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ABSTRACT 
 
Obesity is a global health problem and the current available evidence from the 
literature suggests that obese women may suffer from a wide spectrum of 
reproductive complications. The current understanding of obesogenic effects on 
the peri-implantation endometrium is limited and has become an important 
research topic as the emerging clinical evidence from the published studies 
indicate the possible role of the endometrium. 
 
The first part of this thesis addresses the clinical question of whether an early 
pregnancy outcome is affected by the body mass index and whether there is 
any difference in time taken to achieve pregnancy in obese women with 
recurrent miscarriage when compared to normal weight women. The results are 
in chapters 3 and 4, where we demonstrated that obese women were more 
likely to have miscarriage of empty gestational sac or anembryonic 
pregnancies. In recurrent miscarriage context, the obese women were more 
‘super-fertile’ suggesting the possible loss of an endometrial ability to select 
normal from abnormal pregnancies.   
 
The second part of this thesis provides an analysis of the peri-implantation 
endometrial stromal compartment in normal weight and obese women. In 
chapter 5, using immunohistochemical methods it was shown that there was no 
difference in the uterine natural killer cell and macrophage density in the peri-
14 
 
implantation endometrium of different weight groups. This suggests that the 
endometrial dysfunction in obese women with reproductive failure does not 
appear to be immune cell mediated. 
 
In chapter 6 it was shown that the clonogenecity of endometrial mesenchymal 
stem cells (W5C5+) was significantly negatively correlated with the BMI. The 
obese women had significantly reduced cloning efficiency of W5C5+ cells when 
compared to normal weight women, suggesting of a possible sub-optimal 
regenerative capacity of the endometrium in obese women. 
 
Finally, chapter 7 showed a potential association between obesogenic 
environment and impaired stromal cell decidualisation. Using an in-vitro model, 
it was shown that there was no significant difference in the expression of 
decidualisation markers (PRL and IGFBP1) in the decidualising endometrial 
stromal cells from normal weight women when compared to high BMI women. 
However, when the stromal cells were decidualised in an artificial obesogenic 
environment, the PRL expression was significantly inhibited in the presence of 
supernatant from adipose tissue explants of obese women when compared to 
normal weight women. 
 
In summary, the findings from my work have provided an understanding of the 
peri-implantation endometrium in obese women and evidence to suggest that 
the endometrial stromal function is possibly facilitated by metabolic influences. 
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1.1 OBESITY  
 
1.1.1 Definition  
 
Obesity, defined as an abnormal or excessive fat accumulation that may impair 
health, is a complex condition that has serious physical, psychological and 
social consequences for an individual (WHO Fact sheet, Mar 2013). The central 
origin of this excessive fat accumulation results from an energy imbalance that 
results when an excessive intake of calories exceeds calories expenditure.  
 
It is difficult to directly measure body fat and its distribution. The body weight 
may not provide an accurate estimation of the fat stores in the body. Hence, 
other measurements such as body mass index (BMI), waist to hip ratio, waist 
circumference, skin fold thickness and bio-impedance are being used to 
evaluate and define obesity (Haththotuwa et al., 2013). BMI is calculated by 
dividing weight in kilogrammes by the square of the height in meters (kg/m2). 
BMI is relatively easy to calculate, non-invasive, inexpensive and reproducible 
(National Obesity Observatory, 2009). The BMI increases as the amount of 
body fat increases and increases the subsequent risk of obesity related illness 
(National Heart Foundation 2007). Though BMI is not the ideal measure of body 
fat, it has been the most widely accepted measure to estimate normal weight, 
overweight or obese, as in most people it compares well with their body fat 
levels (National Obesity Observatory, 2009). It is considered that body fat 
20 
 
distribution is more relevant than the actual weight as the visceral fat is 
metabolically more active and is responsible for the increased metabolic and 
cardio-vascular risks (Lord and Wilkin, 2002). However, the true measures of 
body fat using bio-impedance are impractical or expensive to use at population 
level. The waist:hip ratio and waist circumference are more strongly associated 
with metabolic risks and long term illnesses and should be ideally be used to 
define obesity, but it may be difficult to measure these, especially in obese.  
 
1.1.2 Extent of the problem 
 
Obesity is a global health problem. It was once considered as a being 
associated with affluence, but now, it can virtually affect all socio-economic 
ranks and age groups. According to WHO global estimates in 2008 more than 
1.4 billion adults aged 20 and older were overweight and about half a billion of 
them were obese - nearly 300 million women and over 200 million men (WHO 
Fact sheet updated March 2013). At least 2.8 million people die each year as a 
consequence of being overweight and obese (WHO 10 facts about obesity, 
2013). The highest prevalence of obesity has been reported be over 75% in 
Samoa and Nauru whereas it is less than 5% in China, Japan, India and certain 
African nations (WHO Global database on body mass index, update January 
2014). There has been a tremendous increase in the prevalence of obesity in 
England in the last two decades and it is estimated that around one in four adult 
is now classified as obese – 24% of men and 26% of women (Craig and 
Mindell, HSE, 2010).  
21 
 
 
 
Classification 
 
BMI (kg/m2) 
 
Principle cut-off points      Additional cut-off points 
 
Underweight                                  < 18.50                                 < 18.50 
  Severe thinness                          < 16.00                                 < 16.00 
  Moderate thinness                  16.00 - 16.99                          16.00 - 16.99 
  Mild thinness                           17.00 - 18.49                          17.00 - 18.49 
 
Normal                                        18.5 - 24.9                           18.50 - 22.99 
                                                                                   23.00 - 24.99 
 
Overweight                                   ≥ 25.00                                   ≥ 25.00 
  Pre-obese                                 25.00 -29.99                         25.00 - 27.49 
                                                                                       27.50 - 29.99 
 
Obese                                           ≥ 30.00                                  ≥ 30.00 
  Obese Class I                        30.00 – 34.99                         30.00 – 32.49 
                                                                                 32.50 – 34.99 
  Obese Class II                       35.00 – 39.99                         35.00 – 37.49 
                                                                                  37.50 – 39.99 
  Obese Class III                           ≥ 40.00                                  ≥ 40.00 
 
Table I: The International Classification of adult underweight, overweight and obesity 
according to BMI (Source: WHO – Global database on body mass index, updated 
January 2014.) 
 
22 
 
1.1.3 Impact on health and resources 
 
Obesity exerts adverse metabolic effects on blood pressure, insulin resistance, 
triglycerides and cholesterol. The risk of acquiring non communicable diseases 
such as cardiovascular diseases (ischaemic heart disease and cerebrovascular 
accidents), diabetes, musculoskeletal disorders (osteoarthritis) and cancers 
(endometrial, breast and colon) are higher in overweight and obese individuals 
(WHO Fact sheet updated March 2013). It causes significant burden on the 
health resources and in England, it is estimated that £5.1 billion per year is 
being spent on managing the effects directly caused by obesity (Craig and 
Mindell, HSE, 2010).). Considering its serious implications on health and 
resources, WHO in 1997, formally recognised obesity as a major public health 
problem and a ‘global epidemic’. 
 
1.2 Obesity and Female Reproductive Health 
 
The effects of obesity on reproduction start in children. The onset of puberty 
and menarche is earlier in obese girls when compared to their normal weight 
peers (Must et al., 2005; Himes, 2006). Consequences of early sexual 
development can generate psychosexual strain in young girls and their families 
(Lash and Armstrong, 2009). In animal studies, it has been demonstrated that 
leptin injection triggers the onset of puberty (Ahima et al., 1997) and in leptin 
deficient adolescent girl with proven hypogonadotrophic hypogonadism it has 
23 
 
been shown that leptin substitution led to a rapid induction of gonadotropin 
secretion and menarche (von Schnurbein et al., 2012). It is possible that large 
volumes of adipose tissue in obese children generate increased leptin levels 
that trigger the onset of puberty. Also, the bioavailability of sex steroids is more 
in obese girls due to increased aromatization of androgens in the adipose 
tissue, which stimulates earlier puberty (Ahmed et al., 2009). The risks of 
developing hyperandrogenism and PCOS are more common in girls with an 
early onset of puberty (Ibanez et al., 2009). 
 
Heavy menstrual bleeding (HMB) is defined as excessive menstrual blood loss 
(MBL) that affects a woman’s physical, social, emotional or material quality of 
life (NICE, 2007). HMB, with a more objective definition of total MBL of 80 ml or 
more (Warner et al., 2004), is a source of considerable morbidity to women. 
There is a lack of evidence in the literature to establish the impact of increased 
BMI upon quantity of MBL among women with HMB. Dysfunctional uterine 
bleeding is more common in overweight women as a result of aromatization of 
androgen to oestrogen in adipose tissue and thus altering the oestrogen-
progesterone ratio. This prolonged excessive oestrogen stimulates endometrial 
proliferation and overgrowth leading to bleeding at irregular intervals (Lash and 
Armstrong, 2009). Weight loss may restore menstrual regularity in these women 
by reduction in the peripheral conversion of androgen to oestrogen. 
 
Pre-menopausal obese women appear to have increased risk of developing 
endometrial polyps that may be associated with abnormal uterine bleeding. In a 
24 
 
survey, obesity in combination with hypertension was found to be a significant 
risk factor for the development of endometrial polyps (Resolva et al., 1999). In 
women undergoing IVF, BMI was found to be an independent risk factor for the 
development of endometrial polyps (Onalan et al., 2009). 
 
In 2006, ESHRE Capri Workshop Group looked at nutrition and female 
reproduction, and summarised the available evidence on the effects of obesity 
on contraception. They concluded that combined oral contraceptive pills, 
contraceptive patches, progesterone only pills, contraceptive implants and the 
use of tubal rings for female sterilisation were less effective in women with 
increased body weight (ESHRE Capri Workshop Group, 2006).  Variations in 
steroid metabolism and distribution, sequestration of steroids in adipocytes and 
dilution of the steroids in a larger blood volume were thought to be responsible 
for the reduced effectiveness of hormonal contraceptives in obese women. 
However, a recent Cochrane Database Systematic Review looked at the data 
from 13 trials that included 49,712 women, for the effects of BMI on 
contraception. Out of the five reports that compared BMI groups, only one trial 
suggested that women with a BMI of more than 25 were at a greater pregnancy 
risk and the other four trials did not show significant difference. The authors 
concluded that evidence did not show an association of BMI and hormonal 
contraceptive efficacy, and that the evidence was limited to assess the 
effectiveness of any individual contraceptive method (Lopez et al., 2013).  
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There is a strong association between obesity and endometrial cancer (Kaaks 
et al., 2002). Chronic exposure of the endometrium to unopposed oestrogen 
associated with PCOS causes endometrial proliferation and potential malignant 
changes. Further to this, hyperinsulinaemia and hyperandrogenism associated 
with obesity decrease the availability of SHBG leading to increased 
bioavailability of oestrogen, which further accentuates the deleterious effects of 
oestrogen on the endometrium (Kulie at al., 2011). Obese women are more 
likely to have increased incidence and mortality from cervical cancer and this 
may partly be due to poor compliance of obese women for the cervical 
screening programme (Maruthur et al., 2009). Increased serum oestradiol levels 
are also responsible for the increased development of breast cancer in obese 
women (Kuhl, 2005). 
 
1.2.1 Obesity and Female fertility  
 
Hippocrates wrote: ‘People of such constitution cannot be prolific . . . fatness 
and flabbiness are to blame. The womb is unable to receive the semen and 
they menstruate infrequently and little’ (Lloyd, 1978). While a women’s body fat 
is a vital prerequisite for reproductive efficiency and pregnancy, an extreme 
increase appears to lead to poor reproductive outcomes such as infertility, 
increased risk of miscarriage and a poor response to ART (Lewis et al., 1990).    
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1.2.1.1 Effects on sexual dysfunction 
 
There is an increasing evidence to suggest that obesity not only affects physical 
health, but also has an adverse impact on sexual health. Sexual dysfunction is 
found to be more common in obese women when compared to slim women 
(Shah, 2009). The frequency of penile-vaginal intercourse is greater in slimmer 
women as measured by smaller waist and/or hips (Brody, 2004). Obese women 
may suffer from lack of libido and sexual satisfaction, have difficulty with sexual 
performance and avoid sexual encounters (Kolotkin et al., 2006). This may be a 
result of amalgamation of factors to include physical, psychological, hormonal, 
physiological, emotional, reproduction and social. In general slimmer physique 
is considered to be physically more attractive and as they are at a lower risk of 
metabolic, cardiovascular and malignant disorders, the potential partners react 
similarly, especially with regards to sexual behaviour (Brody, 2004). Obese 
women have difficulty in commencing sexual relationship because of low self-
confidence about their physique and the associated symptoms of 
hyperandrogenism such as acne and hirsuitism. Associated medical conditions 
such as musculoskeletal disorders, urinary incontinence and menstrual 
disorders may restrict sexual function in obese women. Women with high BMI 
have lesser indices of brain dopamine activity (Doknic et al., 2002) and the 
association of overeating with increased serotonin levels in the brain 
(Hussanain and Levin, 2002) may result in poor sexual desire and increase 
sexual dysfunction.  
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1.2.1.2 Effects on fecundability 
 
Many studies have reported an association between obesity and reduced 
fecundability or the probability of conceiving a pregnancy for a given cycle 
(Bolumar et al., 2000; Rich-Edwards et al., 2002; Hassan and Killick, 2004; 
Gesink Law et al., 2007; Yilmaz et al., 2009). It is possible that increased 
oestrogen levels as a result of increased peripheral conversion of androgen to 
oestrogen in adipose tissue, decreased availability of gonadotropin releasing 
hormone could impede with hypothalamic-pituitary-ovarian control of ovarian 
function resulting in anovulatory cycles (Pralong et al., 2002; Haslam and 
James, 2005). 
 
Impaired fertility has also been established in women with regular menstrual 
cycles. A retrospective data (Gesink Law et al., 2007) demonstrated a reduced 
fecundity for overweight (OR 0.92, 95% CI 0.84 – 1.01) and obese women (OR 
0.82, 95% CI 0.72-0.95). A large retrospective cohort study of 22,840 women 
demonstrated an association between obesity and reduced fecundity for all 
weight-adjusted groups of women (Yilmaz et al., 2009). Both these studies 
showed that the effect of reduced fecundity persisted even for women with 
regular cycles. The finding of reduced fecundity with regular menstrual cycle i.e. 
regular ovulation may be due to the possible effects of obesity on the 
endometrium or on the fertilization potential of the oocyte. 
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1.2.1.3 Effects on natural fertility 
 
About 1 in 6 couple experience infertility. Most obese women are able to 
achieve pregnancy readily and anecdotally, many morbidly obese women do 
not have any difficulty achieving a pregnancy. Howe et al. (1985) suggested 
that height, weight or Quetelet’s index did not show any significant association 
with fertility. A retrospective cross-sectional survey of 1081 women suggested 
that infertile women when compared to women without infertility had a 4.8 fold 
increase in being obese (OR = 2.02, 95% CI, 0.70 – 5.84) and 3.8 fold 
increased risk of being overweight (OR = 2.11, 95% CI, 0.72 – 6.07) 
(Esmaeilzadeh et al., 2013). A nested case control study (Nurses’ Health study) 
analysed 2527 married nulliparous nurses with ovulatory infertility of at least 1 
year and compared them to 46,718 married parous controls with no infertility. 
The multivariate relative risk of primary ovulatory infertility at the age of 18 was 
1.3 fold higher (95% CI 1.2-1.6) for women with BMI of 24-31 and 2.7 fold more 
(95% CI 2.0-3.7) for women with a BMI of more than 32 (Rich-Edwards et al., 
1994). The Nurses’ Health study II by the same group suggested that ovulatory 
infertility was associated with overweight and sedentary lifestyle than 
underweight and overexertion (Rich-Edwards et al., 2002). It is likely that high 
BMI has a negative impact on natural fertility as a possible result of various 
factors. 
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1.2.1.4 Does weight loss improve fertility? 
 
There is good evidence and a better understanding of the positive effects of 
weight reduction on improved reproductive outcome. A multi-centre, 
prospective, randomized, double blind, placebo controlled study assessed the 
effects of lifestyle measures plus placebo to lifestyle measures and metformin 
on changes in menstrual cycle, anthropometric measures and endocrine 
parameters in obese anovulatory PCOS women. The study elegantly showed 
that both groups of women showed a significant improvement in weight loss and 
increase in menstrual frequency (Tang et al., 2006).  Norman et al. (2004) 
reviewed the available evidence on the effects of weight management and 
dietary intervention in improving female reproductive function and suggested 
that in obese women even a modest weight loss of about 10% could effectively 
improve ovulation, menstruation, pregnancy rates and hormonal profile. The 
review suggested that weight loss in PCOS women was found to improve 
insulin sensitivity, normalising androgen excess, decreased hyperlipidaemia 
and ovarian p450c17α activity. Ferlitsch et al., (2004) analysed results of 171 
women who underwent IVF or ICSI with particular reference to variations in BMI 
and day 3 FSH levels. They demonstrated that by increasing BMI by one unit, 
the odds for pregnancy decreased by 0.84 (95% CI 0.73-0.97). This suggests 
that chance of pregnancy increases with weight loss and any decrease in BMI 
by one unit improves pregnancy rates by 19%.  
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1.2.2 What are the effects of high BMI on Infertility treatment? 
 
There is increasing evidence from the clinical studies that an increased BMI 
may be associated with poorer outcomes following treatment for infertility. NICE 
recommends that female BMI should ideally be in the range of 19-30 before 
considering assisted conception treatment, considering the likely reduction in 
treatment success for women outside this BMI range (NICE 2013). Many NHS 
trusts across the UK have female partner’s BMI of ≤ 30 as one of the criteria for 
funding a couple’s infertility treatment.  The BFS guideline also recommends 
aiming for a normal BMI before considering any fertility treatment. It also 
advises clinicians to defer treatment until the BMI is less than 30 in women 
under the age 37 years and with normal ovarian reserve and that the treatment 
should not be offered to women with BMI ≥ 35 (Balen and Anderson, 2007).     
 
1.2.2.1 Ovulation Induction 
 
Clomiphene citrate remains one of the first line treatments for anovulatory 
infertility. Imani et al. (1998) demonstrated that in 201 normogonadotrophic, 
oligomenorrhoeic or amenorrhoeic infertile women who underwent ovulation 
induction (OI) with clomiphene citrate, 22.5% were clomiphene resistant and did 
not ovulate. The BMI was significantly more in the resistant group than in the 
responders and high BMI was found to be one of the predictors for women 
remaining anovulatory after clomiphene citrate OI. 
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Gonadotrophins are one of the second-line treatments for OI in clomiphene 
resistant anovulatory women. A meta-analysis that looked at 13 studies 
suggested that the total dosage of gonadotrophins required was more (WMD of 
771 IU, 95% CI 700 – 842) in obese women with a significantly reduced 
ovulation rate (pooled OR 0.44, 95% CI 0.31 – 0.61) and an increased chance 
of cycle cancellation (pooled OR 1.86, 95% CI 1.13 – 3.06) (Mulders et al., 
2003). The results of two large, multicentre OI studies that assessed the 
influence of obesity on OI outcome, suggested that obese women required a 
significantly higher dose of gonadotrophins and a longer duration of stimulation, 
and produced significantly fewer large follicles, but had no overall effect on 
ovulation and pregnancy rates (Balen et al., 2006).  
 
1.2.2.2 Superovulation and in-utero insemination 
 
A university-based, retrospective chart review of 333 ovulatory women who 
underwent superovulation and IUI for infertility treatment demonstrated that in 
obese women when compared to normal weight women, the adjusted cycle 
fecundity was no different, but the total gonadotrophin dose required was more 
and levels of oestradiol were less, but there was no difference in the number of 
larger follicles (Dodson et al., 2006). However, a retrospective study found that 
obesity was associated with a lower number of medium, large and total follicles 
for a given dosage of gonadotrophins, but no difference in the clinical 
pregnancy and miscarriage rates (Souter et al., 2011). 
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1.2.2.3 Assisted Reproduction 
 
There is inconsistent evidence regarding the effects of obesity on ART 
outcome. Some studies have suggested that the BMI did not affect pregnancy 
rate after IVF treatment (Lashen et al., 1999; Matalliotakis et al., 2008), but the 
systematic reviews of observational studies, mainly retrospective, have 
demonstrated a possible harmful effect of obesity on pregnancy outcome 
(Maheshwari et al., 2007; Rittenberg et al., 2011a).  
 
Pooling of results from five studies in a systematic review and meta-analysis 
that looked at IVF treatment outcomes reported a statistically significant 
decrease in the live birth rates in obese women and in the clinical pregnancy 
rates in overweight (pooled data from 16 studies) and obese women (pooled 
data from 15 studies) when compared to women with normal BMI (Rittenberg et 
al., 2011a).  The same review also reported that obese women required more 
total dose of gonadotrophin and a longer duration of stimulation.  
 
McLernon et al. (2010), in their meta-analysis evaluating the use of single 
embryo transfer on IVF outcome showed that for every unit increase in BMI, the 
odds of a very preterm delivery ≤ 32 weeks was increased by 16% (OR 1.16, 
95% CI 1.04-1.30). Inherent bias is a common problem with pooling of 
observational studies data as it is difficult to adjust for confounding factors such 
as age, cause of infertility and the number and quality of embryos transferred.  
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A single largest study that looked at 31,672 ART embryo transfers from the 
Society of Assisted Reproductive Technology Clinic, which permitted 
adjustment for age, parity, number of embryos transferred and the embryo 
transfer day, showed that failure to achieve a clinical intrauterine gestation was 
significantly more likely for obese women (RR:1.22, 95%CI: 1.13-1.32) (Luke et 
al., 2011). However, a recent systematic review (Koning et al., 2012) that 
included 27 studies found no significant decrease in the rates of clinical 
pregnancy, ongoing pregnancy and live birth following ART in overweight and 
obese women when compared to normal weight women and the authors 
conclude that ART should not be restricted based on BMI.  
 
There is a lack of good quality evidence to highlight the effects of woman’s BMI 
on ART success and on the risk of complications. There is a real need for future 
well-designed prospective studies which should take into consideration co-
morbidities and other factors, to advice clinicians of the likely effects of high BMI 
on ART outcome. 
 
1.2.3 Obesity and Miscarriage 
 
Spontaneous miscarriage affects 12-15% of all pregnancies (Zinman et al., 
1996) and it is estimated that the risk of miscarriage in obese women may be as 
high as 25-37% before a first successful pregnancy (Hamilton-Fairley et al., 
1992). Obesity is proposed to be an independent risk factor for early pregnancy 
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miscarriages (Fedorcsák et al., 2000). Most of these miscarriages occur in early 
pregnancy before 12 weeks of gestation.  
 
Metwally et al., (2008), in their systematic review and meta-analysis of sixteen 
studies that investigated the association between obesity and miscarriage, 
showed that women with BMI of ≥ 25 had a significantly higher odds of 
miscarriage, irrespective of method of conception (OR 1.67, 95% CI 1.25-2.25). 
 
The available evidence for miscarriage following spontaneous conception is 
based on a systematic review (Boots and Stephenson, 2011) that included 
three retrospective studies and one prospective study with a large cohort of 
women (n=24,738). The findings suggested that the risk of a miscarriage 
following spontaneous conception increased by 31% for obese women (OR 
1.31, 95% CI 1.18-1.46) and 11% for overweight women (OR 1.11, 95% CI 1.00 
– 1.24) when compared to women with normal BMI. None of the included 
studies in this systematic review had a sample size calculation and the pooled 
analysis did not account for maternal age and gestational age at miscarriage.  
 
Pooled data from 22 observational studies, mainly retrospective, in a systematic 
review (Rittenberg et al., 2011a) that looked at ART treatment outcomes 
demonstrated a significantly increased risk of miscarriage in women with BMI ≥ 
25 when compared to normal BMI women (RR 1.31, 95% CI 1.18 – 1.45, 
p<0.00001, I2 = 47.9%). There was no reported significant heterogeneity in the 
35 
 
included studies. Two studies in this systematic review were prospective with 
the rest retrospective and only one study was case-control whereas the rest 
were cohort studies. There was no adjustment for important confounders such 
as maternal age and the number and quality of embryos transferred, all of which 
are important predictors of ART success. 
 
Rittenberg et al., (2011b) demonstrated that women with BMI ≥ 25 had more 
than double the risk of miscarriage when compared to normal BMI women in 
fresh and cryo thawed single blastocyst transfer ART cycles. When confounding 
variables such as female age, duration and cause of infertility, previous 
miscarriage, smoking status and quality of blastocyst replaced were adjusted, 
the odds of miscarriage was significantly higher for women with BMI ≥ 25 in 
fresh (OR 2.7, 95% CI 1.5-4.9) and cryo-thawed (OR 6.8, 95% CI 1.5-31.1) ART 
cycles and concluded high BMI as an independent risk factor. 
 
There is much debate on the possible association between female obesity and 
miscarriage and most of the evidence comes from retrospective studies and 
systematic reviews of these studies which suggest of a possible increased risk 
of miscarriage both in spontaneous conceptions and pregnancies following 
ART. Maternal age has a significant effect on the miscarriage which is not 
controlled in most of these studies. There is an urgent need for well-designed 
prospective studies that can provide appropriate evidence on the effects of BMI 
on miscarriage and in understanding the underlying mechanisms, which will be 
invaluable in counselling women about these risks. 
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1.2.4 Obesity and Recurrent Miscarriage 
 
The loss of three or more consecutive miscarriages before 24 weeks of 
gestation is traditionally termed as recurrent miscarriage (RM) and it affects 1-
2% of the couple trying to achieve a pregnancy (Stirrat GM, 1990). In about 
50% of all cases, the cause remains unknown despite a wide range of 
investigations (idiopathic RM) and in the remaining, the known aetiological 
factors include genetic, thrombophilic, endocrine, immune, infection and 
anatomical or structural causes (RCOG green-top guideline, 2011).  
 
Two retrospective studies (Lashen et al., 2004; Metwally et al., 2010) have 
analysed the association between obesity and RM. A matched case control 
study by Lashen et al. (2004) that included 1644 obese and 3288 normal weight 
women with a mean age of 26.6 years showed a significantly higher odds of RM 
in obese women (OR 3.51, 95% CI 1.03 – 12.01). Metwally et al., (2010) looked 
into a total of 844 pregnancies from 491 women with RM and found out that 
obese women, when compared to women with normal BMI had a significantly 
increased odds of miscarriage in a subsequent pregnancy (OR 1.71, 95% CI 
1.05 – 2.8). Using logistic regression analysis, they analysed the data further to 
conclude that advanced maternal age was the most important predictor of 
miscarriage followed by increased maternal BMI.   
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1.3 Metabolic effects of obesity on reproduction 
 
From the available clinical studies, it is evident that the obesogenic environment 
has an adverse effect on reproductive outcomes, but the mechanism by which 
obesity causes increased reproductive failures is not fully understood. It is 
possible that the metabolic disturbances associated with obesity may exert 
effects on the ovary, the embryo and endometrium. The obese environment 
may also cause perturbations in hormonal balance that control ovulation and 
endometrial development. 
 
1.3.1 Effects on ovary 
 
1.3.1.1 Polycystic ovarian syndrome (PCOS) 
 
PCOS is a common endocrine disorder in women of reproductive years with a 
prevalence as high as 15% (Fauser et al., 2012), and is responsible for 90-95% 
of women with anovulatory infertility attending infertility clinics (Balen and 
Anderson, 2007). Obesity is common in women with PCOS and it is estimated 
that at least 35-40% of women with PCOS are obese (Hamilton-Fairlley et al., 
1992; Balen et al., 1995). Some studies have reported a prevalence of obesity 
to be as high as 61-76% in American and Australian PCOS women (Ching et 
al., 2007; Glueck et al., 2005). Though obesity is closely linked to PCOS, the 
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mechanism to understand the evolution of obesity and PCOS are not fully 
understood (Fauser et al., 2012).  
 
The Rotterdam consensus workshop (2004) set out diagnostic criteria to 
diagnose PCOS which included cardinal features of ovulatory dysfunction 
hyperandrogenism and polycystic ovary morphology. Ovulation dysfunction is 
characterised by chronic oligo or anovulation represented by oligomenorrhoea 
or amenorrhoea. In a cohort of Srilankan women, 95% of PCOS women were 
found to have oligo- or amenorrhea (Kumarapeli et al., 2008). Ovulation in 
PCOS women may occur spontaneously in up to 32% of the cycles, but the 
frequency of ovulation is unknown (Laven et al., 2002). The extent of ovulatory 
dysfunction, androgen levels and follicular count depends on whether a PCOS 
woman has oligo-ovulation or anovulation (Burgers et al., 2010).  
 
Hyperandrogenism in women clinically presents as hirsuitism, acne and 
androgenic alopecia, and are present in about 74%, 53% and 34.8% 
respectively of women with PCOS (Ozdemir et al., 2010). Hyperandrogenaemia 
or excessive circulating free androgen levels may either be due to excessive 
production from the ovary or adrenal glands or by a decreased SHBG synthesis 
in liver. A proportion of PCOS women may not exhibit hyperandrogenaemia 
(Pugeat et al., 1993; Balen et al., 1995; Laven et al., 2002). Many PCOS 
women have insulin resistance (IR), defined as decreased insulin-mediated 
glucose utilisation with compensatory hyperinsulinaemia (Dewailly, 1997). In 
women with PCOS, the degree of metabolic dysfunction correlates strongly with 
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the amount of visceral fat, which either causes or pre-disposes a woman to IR 
(Lord et al., 2006). Increased visceral adiposity is associated with greater IR, 
which could exacerbate the abnormalities in reproductive function of women 
with PCOS (Balen and Anderson, 2007). Although IR can occur irrespective of 
BMI, the association of PCOS and obesity have a synergistic adverse impact on 
glucose homeostasis and worsen both hyperandrogenism and anovulation. The 
hyperandrogenism and hyperinsulinaemia along with other extra and intra-
ovarian factors in PCOS may adversely affect oocyte and embryo quality (Qiao 
and Feng, 2011). Hyperinsulinaemia is found to be an independent risk factor 
for first trimester miscarriages with an OR of 1.32 (95% CI 1.09-1.60) for every 
5 µIU/ml increment in insulin levels (Glueck et al., 2002).  
 
1.3.1.2 Ovarian dysfunction 
 
It is proposed that obesity may cause an adverse effect on the ovarian function 
either by its metabolic effects on ovulation or on the oocyte quality. In ART 
cycles, controlled ovarian hyperstimulation (COS) is undertaken to obtain 
sufficient number of oocytes and it is suggested that the ovaries in obese 
women may be more resistant to COS. However, two systematic reviews 
(Maheshwari et al., 2007; Ritteberg et al., 2011) have pooled the results of 
mainly retrospective observational studies that looked into the effects of 
overweight and obesity on ART cycles and both concluded that there was no 
difference in the number of oocytes recovered in different BMI groups. The most 
recent systematic review and meta-analysis pooled the results from five studies 
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that compared the duration and total dosage of gonadotrophins used for COS in 
different weight groups. The review reported that obese women required a 
higher dose of gonadotrophin stimulation (WMD 406.77, 95% CI 169.26-644.2, 
p=0.0008) and a longer duration of stimulation (WMD 0.27, 95% CI 0.26-0.28, 
p<0.00001) when compared to women of normal BMI. Though there was a 
significant heterogeneity between the included studies that reported the dose of 
gonadotrophins used (I2 = 80.8%), there was no significant heterogeneity 
between the included studies for the duration of gonadotrophins used (I2 = 0%) 
(Rittenberg et al., 2011). The risk of ART cycle cancellation (pooled data from 3 
studies out of which two were due to poor response) was higher in women with 
BMI>30 with an OR 1.34 (95% CI 0.99-1.84) when compared to women with 
BMI <30. This suggests that obese women when compared to normal weight 
women, to produce similar number of oocytes in response to COS in ART 
cycles’ require longer duration of gonadotrophins stimulation and possible more 
gonadotrophins. It is well recognised that drug bioavailability is decreased and 
drug distribution is altered in obese women, which may explain these findings.  
 
The evidence on the effects of obesity on oocyte quality is conflicting.  It has 
been accepted that on a morphological assessment, an oocyte with a clear to 
colourless zona pellucida, clear or moderately granular cytoplasm and a small 
perivitelline space is considered a good quality metaphase II oocyte (Veeck, 
1988). Wittemer et al. (2000) morphologically analysed the oocytes obtained 
from women undergoing IVF or ICSI (332 cycles with long protocol, 50 cycles 
with short protocol and 16 cycles without gonadotrophins) and showed that 
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women with BMI ≥ 25 had significantly poor quality oocytes retrieved when 
compared to the oocytes obtained from women with BMI <25. 
 
During IVF, hCG is given in a higher dose (5,000-10,000IU) to imitate mid-cycle 
LH surge and hcg when present in adequate levels in the stimulated follicles, 
helps in the completion of the first meiotic division of an oocyte to become a MII 
oocyte and ready to undergo fertilization. Using this principle, Carrell et al., 
(2001) prospectively assessed follicular fluid hCG concentrations from 247 
consecutive IVF cycles and demonstrated a significant inverse correlation 
between intra-follicular hCG concentration and BMI. They also found 
significantly reduced mean hCG concentration, poor embryo quality and 
decreased clinical pregnancy rates in women with BMI ≥ 30 when compared to 
women with BMI 20-30, but no difference in oocyte quality.  
 
The principal mechanisms that govern the appearance of an oocyte are multi-
factorial and complex and make the morphological assessment of an oocyte a 
difficult process (Balaban and Urman, 2006). Hence, fertilization rate in ART 
cycles is considered a surrogate marker and a more objective way of predicting 
oocyte quality. Fedorcsak et al., (2004) in their large cohort of 5019 IVF or ICSI 
cycles did not find a significant correlation of BMI to diploid fertilization rates. 
Dokras et al., (2006) demonstrated that there was no significant difference in 
the fertilization rates, the number of embryos transferred and cycle cancellation 
as a result of failed fertilization in different BMI groups. A retrospective analysis 
of 426 IVF/ICSI cycles that assessed the fertilization rates between different 
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BMI groups suggested that obesity did not have any significant effect on oocyte 
quality (Metwally et al., 2007). Esinler et al. (2008) looked at the impact of 
isolated obesity on the outcome of ART in a total of 775 patients undergoing 
1113 ICSI cycles. They reported reduced number of cumulus-oocyte complex, 
MII oocytes and oocytes with 2 pro nuclei in obese women compared to women 
with normal BMI, but did not find any significant difference in fertilization rates. A 
large retrospective analysis of 6500 IVF cycles failed to establish an association 
between BMI and the number and maturation of oocytes and fertilization rates, 
but clearly showed a reduction in implantation, pregnancy and live birth rates 
(Bellver et al., 2010).  Another retrospective cohort study of 1,721 women 
undergoing a first IVF cycle with fresh, autologous embryos between 2007 and 
2010 concluded that the number of oocytes at metaphase II stage and the failed 
fertilization rates were comparable in different BMI groups (Shah et al., 2011).  
 
In conclusion, negative environmental influence may affect the developmental 
competence of the oocyte and the available evidence suggests that obesity 
when associated with PCOS may affect ovarian function by altering regular 
ovulation. The systematic reviews of the studies have produced conflicting 
results. The number of oocytes produced by obese women in response to COS 
in ART cycles is found to be similar to normal weight women suggesting that the 
metabolic effects of obesity may not be mediated through ovarian function. 
However, it is essential to recognise that the evidence comes mainly from 
retrospective cohort studies. Also, there is no good quality evidence from 
morphological assessment of oocytes and fertilisation rate as a surrogate 
marker, to conclude that obesity has negative influence on oocyte quality. 
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1.3.2 Effects of obesity on an embryo 
 
Successful implantation of an embryo into the endometrium is an intricate 
procedure that depends on the synchronized cross-talk between a 
developmentally competent embryo and a receptive endometrium (Dey et al., 
2004). Chromosomal abnormalities are common in pre-implantation embryos. 
Any alteration during meiosis would result in abnormality in all the cells whereas 
any error during the first mitotic division is responsible for chromosomal 
mosaicism (Koot et al., 2012). A study by Munné et al., (2007) looked at more 
than 6000 embryos of which many were suitable for embryo transfer. They 
found that 44% of the embryos with best morphology and development were 
euploid in women under the age 35 and only 21% in women aged 41 or more. 
Vanneste et al. (2009) examined the incidence of chromosomal abnormalities 
by comparative genomic hybridization screening in cleavage stage IVF embryos 
obtained from young fertile women under the age of 35 years. Only two out of 
23 good quality embryos were found to have normal karyotype in all 
blastomeres. Nearly fifty percent of the embryos had karyotypically no normal 
cells and the remaining embryos were mosaic for structural chromosomal 
imbalances. They proposed that the prevalence of chromosomal abnormalities 
in the pre-implantation embryos may be as high as 90%. Karyotype of products 
of conception after three or more consecutive pregnancy losses indicate that 
aneuploidy is the most common cause of RMC (Sugiura-Ogasawara et al., 
2010). An exceptional feature of implantation is to overcome such a high 
prevalence of chromosomally abnormal embryos. Most of the aneuploid 
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pregnancies (90%) miscarry whereas 93% of karyotypically normal pregnancies 
continue – natural embryo selection (McFadden, 1989).   
 
The available clinical evidence indicating the consequences of high BMI on 
embryo quality is inconsistent and debatable (Carrell et al., 2001; Fedorcsak et 
al., 2004; Metwally et al., 2007; Esinler et al., 2008; Zhang et al., 2010; Bellver 
et al., 2010; Zander-Fox et al., 2012). Carrell et al., (2001) observed that 
women with BMI ≥ 30 had significantly poorer quality embryos than in women 
with BMI 20-30. Some authors (Metwally et al., 2007; Esinler et al., 2008) have 
considered overall quality of the embryos produced in an ART cycle and not just 
the embryo grading to assess the overall quality. Metwally et al. (2007) 
assessed four different markers for embryo quality (embryo grade, embryo 
utilization rate, number of embryos discarded and the number of embryos 
cryopreserved) in a retrospective analysis of 426 consecutive IVF cycles and 
reported significantly poor quality embryos in obese women under the age of 35 
years. Esinler et al. (2008) found a significantly less number of surplus embryos 
cryopreserved in obese when compared to normal BMI women (10.7% 
vs.22.7%).  Zhang et al. (2010) in their retrospective cohort study of 2628 
women in China suggested that obese women have lower fertilisation rates, 
fewer cleaved and high grade embryos and fewer embryos for cryopreservation.  
 
However, a large retrospective study on 6500 IVF/ICSI cycles concluded that 
the embryo quality was not impaired in overweight and obese women and 
suggested of a possible endometrial cause for poorer IVF outcomes in obese 
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women (Bellver et al., 2010). There was no association between obesity and 
morphologic characteristics of the embryo found in another retrospective cohort 
study looking at 1721 women undergoing first cycle of fresh IVF treatment 
suggesting that obesity may exert an effect on reproduction without affecting 
embryo quality (Shah et al., 2011). In another retrospective study of IVF cycles, 
BMI did not have an apparent effect the embryo development in women less 
than 38 years of age (Zander-Fox et al., 2012).  
 
In summary, there is again a paucity of good quality evidence to suggest that 
obesity impacts developmental competence of an embryo.  Active research 
need to be undertaken to determine complex interactions of various hormones 
and metabolites in obesity may affect oocyte and embryo quality. Also, there is 
also an urgent need for well-designed studies to assess the effects of weight 
loss on ovarian function as it appears that the intervention may ameliorate the 
negative effects of obesity on reproduction.  
 
1.3.3 Effects of obesity on endometrium 
 
Endometrium plays a major role and is likely to be the most influential factor in 
implantation. Cyclic decidualisation of the human endometrium prepares the 
uterus for implantation of a developmentally competent embryo, to identify and 
reject developmentally abnormal embryos and also prepares the endometrium 
for deep placentation in pregnancy (Teklenburg et al., 2010a). Bellver et al. 
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(2007) suggested that the ovum donation model (that looked at ART cycle 
outcome in oocyte recipients and the oocytes were obtained from healthy 
donors) as an acceptable human model for discriminating the effects of obesity 
on endometrium from its effects on the ovary. Few studies have endeavoured to 
outline the effects of obesity on the endometrium (Wattanakumtornkul et al., 
2003; Styne-Gross et al., 2005; Bellver et al., 2003, 2007, 2013)  
 
A small study from the University of Minnesota looking at 97 women having 
their first cycle of IVF using donor oocytes concluded that uterine receptivity 
was not altered in obese women when hormonal support and embryo quality 
were standardised (Wattanakumtornkul et al., 2003). Bellver et al., (2003), in 
their first study looking at 712 cycles of ART using donor oocytes found that the 
miscarriage rate was fourfold (OR 4.02, 95% CI 1.53-10.57) in obese women 
when compared to women with normal BMI and concluded that obesity is an 
independent risk factor for miscarriage in women receiving donor oocytes.  
 
Styne-Gross et al., (2005) retrospectively looked at data of 536 donor oocyte 
recipients. The donors were healthy females with an average age of 26.8 years 
and an average BMI of 22.2 +/- 2.3. There was no significant difference in 
implantation rates, on-going pregnancy rates and miscarriage rates in obese 
women when compared to women with normal BMI. The ROC curves failed to 
demonstrate BMI as a risk indicator for spontaneous miscarriages.  
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Bellver et al., (2007) investigated 2656 women undergoing first egg donation 
cycles suggested that the on-going pregnancy rate was significantly lower in 
overweight and obese women compared to women with normal BMI and linear 
regression analysis demonstrated a negative trend in pregnancy rates with 
increasing BMI. They concluded that endometrial receptivity was linked to the 
detrimental effects of obesity. The biggest study so far by Bellver et al. (2013) 
which looked at the outcome of 9587 first cycle of egg donation recipients 
showed that implantation, clinical pregnancy and live birth rates were 
significantly reduced in the obese group with no difference in miscarriage rates. 
 
It was argued that co-morbid conditions in the recipients may be contributing to 
the adverse reproductive outcomes in oocyte donation cycles. To overcome this 
factor, DeUgarte et al. (2010) designed a third party assisted reproduction 
models of IVF which was a retrospective study using healthy donor oocytes 
(n=551) and healthy surrogates (n=341) (except for the BMI). A significant 
decrease in live birth rates was observed in women with BMI >35 when 
compared to women with BMI <35. This observation reinforces the other 
findings that impaired endometrial receptivity in obese women is the main 
responsible factor for poor reproductive outcomes. 
 
A retrospective case-control study that looked at data of embryonic karyotype of 
products of conception after surgical evacuation of first trimester miscarriages in 
women less than 40 years of age (n=204), suggested that overweight/obese 
women had an increased rates of miscarriage of euploid embryos (Landres et 
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al., 2010). They concluded endocrine disorders and altered endometrial milieu 
may contribute to these miscarriages. It is plausible that the obesogenic 
environment impairs the peri-implantation endometrium, which may create an 
unfavourable milieu for successful implantation even when embryos are 
karyotypically normal. 
 
In summary, it appears from these studies that an obesogenic environment may 
have a negative influence on the reproductive health of a woman. It is possible 
that an obese woman may take more time to conceive, may have more 
miscarriages, following both spontaneous and assisted conception and may 
have reduced clinical pregnancy and live birth rates following assisted 
conception treatment. Various studies have been undertaken to assess the 
direct, metabolic and endocrinological influence of obesity on reproduction and 
it is interesting to note that the obesogenic effects are likely to be on the 
endometrium and less likely to be on the ovarian function, unless associated 
with PCOS, and on the embryo quality. The exact mechanism by which the 
obesogenic environment affects the peri-implantation endometrial function 
remains to be fully clarified. 
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1.4 Human endometrium 
 
The human endometrium is a multi-layered and an extremely dynamic tissue. It 
cyclically proliferates, differentiates, sheds and then regenerates in response to 
ovarian steroids approximately 400 times in a woman’s reproductive lifespan 
(Jabbour et al., 2006; Brosens and Gellersen, 2006). The endometrium has two 
main components, the stratum functionalis and stratum basalis. The superficial 
functionalis extends from the surface epithelium to endometrial/myometrial 
junction and sheds at each menstruation. The deep stratum basalis is attached 
to the myometrium and encompasses the basal region of endometrial glands, 
dense stroma and large vessels serving as a base for endometrial regeneration. 
The human endometrium is characterised by surface epithelium, cellular stroma 
with stromal fibroblasts, glands, immune cells and blood vessels. The cellular 
composition, structure and function of the endometrium vary throughout the 
menstrual cycle which is divided into three phases – the proliferative, the 
secretory and menstrual. Important changes in phenotype and/or abundance of 
most of these cells occur mainly in the peri-implantation period (Gellersen et al., 
2007) which at functional level are defined as the fertile window, the 
implantation window and the window of natural embryo selection (Teklenburg et 
al., 2010). 
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1.4.1 The phases of endometrial changes in a menstrual cycle  
 
1.4.1.1 The proliferative phase  
 
The proliferative phase is the initial phase of the menstrual cycle that starts 
immediately after menstruation and lasts until ovulation. During the proliferative 
phase of a menstrual cycle, the dominant hormone is ovarian oestradiol which 
encourages structured growth and proliferation of the endometrium. A reduction 
in circulatory oestrogen levels during the last few days of the previous 
menstrual cycle prompts a negative feedback on the hypothalamus to increase 
the secretion of gonadotrophin releasing hormone (GnRH), which in turn 
increases the production and release of follicular stimulating hormone (FSH) 
from the anterior pituitary gland. FSH induces follicular development and 
maturation in the ovaries, in which several antral follicles are recruited to 
develop one mature dominant follicle (Graafian follicle). FSH is responsible for 
proliferation of granulosa cells in the developing follicles, which are the main 
source of oestrogen production. The androgens that are produced in the theca 
cells diffuse into the granulosa cells to be aromatised under the influence of 
FSH to oestrogens – predominantly oestradiol and to a lesser extent oestrone. 
Theca cells and the ovarian stroma also have a small contribution to the 
production of oestrogen. 
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The proliferative changes in the endometrium occur as a result of increasing 
ovarian oestrogen levels. The short endometrial glands elongate and are 
arranged perpendicular to the surface. The epithelium acquires columnar 
features with the nuclei placed at the base. The stromal cells become spindle 
shaped and the spiral vessels form a loose capillary network in the sub-
epithelial region. The adult endometrial mesenchymal stem cells are 
undifferentiated cells present in the basal layer of the human endometrium and 
are hypothesized to be responsible for the cyclical regeneration of the 
functionalis after menstruation (Gargett, 2007). Under the influence of 
oestrogen, several growth factors such as Epidermal growth factor (EGF), 
transforming growth factor (TGF)-alpha, platelet-derived growth factor (PDGF), 
insulin-like growth factors (IGFs) and their binding proteins, fibroblast growth 
factor (FGF), TGF-beta, colony-stimulating factor (CSF)-1 and  vascular 
endothelial growth factor (VEGF) regulate  the proliferation of the endometrium 
(Giudice, 1994; Chan et al., 2004). 
 
1.4.1.2 The secretory phase: 
 
The secretory phase is the next phase of the menstrual cycle that begins with 
ovulation and ceases a few days before menstruation. A rise in the levels of 
oestrogen towards the end of the follicular phase triggers a surge in levels of 
luteinising hormone (LH) and FSH secretion from the anterior pituitary gland. 
This spike in levels of LH results in the rupture of the dominant follicle inducing 
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ovulation. The follicle in the ovary transforms to corpus luteum which secretes 
progesterone.  
 
The changes in the endometrium occur due to the combined effects of 
oestrogen and progesterone and the progesterone can only act on the 
endometrium primed by oestrogen. The surface epithelial cells become more 
columnar and in some places acquire cilia. The glands increase in size and 
show predominant changes. Sub-nuclear vacuolation occurs in the glandular 
epithelial cells (Noyes et al., 1950) in which the vacuoles appear between the 
nuclei and the basement membrane due to accumulation of glycogen. The 
glycogen rich intra-cellular secretion is released into the glandular lumen, which 
then drains into the uterine cavity. The stromal cells undergo morphological and 
biochemical transformation from elongated, spindle-shaped stromal fibroblasts 
into rounded, secretory, epitheloid like decidual cells (Gellersen and Brosens, 
2003). Vascular remodelling occurs that is characterised by development and 
coiling of spiral arteries and growth of subepithelial capillary plexus (Gambino et 
al., 2002). There is a massive infiltration by immune cells mainly the uterine 
natural killer cells (uNK cells) and to a lesser extent macrophages and T cells 
(Bulmer et al., 1991a). 
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1.4.1.3 The menstrual phase: 
 
In the absence of a pregnancy, the ovarian hormone levels decrease as a result 
of the degenerating corpus luteum. The decline in ovarian steroids induces a 
series of vascular, molecular and cellular changes by expression of cytokines, 
chemokines and matrix metalloproteinases and cause shredding of the 
superficial layer of endometrium which results in menstruation (Jabbour et al., 
2006; Brosens and Gellersen, 2006). 
 
1.4.2 The functional periods of menstrual cycle 
 
1.4.2.1 The fertile window 
 
The probability of achieving a pregnancy is highest with intercourse occurring 
near the time of ovulation. A prospective cohort study by Wilcox et al., (1995) 
analysed 625 ovulatory cycles in 217 women who were planning to achieve a 
pregnancy. They suggested that the conception can only occur with sexual 
intercourse on or during five days prior to ovulation. This period of six days just 
prior to ovulation and ending on the day of ovulation is termed as the‘fertile 
window’ (Wilcox et al., 1995).  However it is possible that there is a variation in 
the length of the fertile window between couples and in different menstrual 
cycles. A prospective study that looked at the fertile window among subfertile 
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couples, based on sperm-mucous interaction, concluded that the fertile window 
is variable from <1 day to >5 days (Keulers et al., 2007). Based on the above, it 
would be tempting to assume that an extended fertile window would increase 
fertilization and conception rates, but in normal couples, fertilization does not 
appear to be the rate-determining step (Teklenburg et al., 2010 a). 
 
1.4.2.2 The implantation window 
 
The post-ovulatory rise in progesterone mediates changes within the 
endometrium and prepares it to respond to embryonic signals. This transient 
period of endometrial receptivity is termed as the ‘implantation window’, which 
starts around six days after ovulation and lasts for about four to five days 
(Macklon et al., 2002). This restricted duration of implantation window may be 
responsible to orchestrate embryonic development with that of the endometrial 
preparation (Wilcox et al., 1999) and also decreases the possibility of a late 
implantation of poor quality embryos. Further restriction of this crucial 
implantation window causes subfertility and IVF treatment failures (Boomsma et 
al., 2009; Devroey et al., 2009). Late implantation of the embryos is associated 
with an increased risk of early miscarriage (Wilcox et al., 1999). Hence it is 
possible that prolonged expression of endometrial receptivity carries the risk of 
allowing developmentally slow or poor quality embryos to implant thus 
increasing implantation rates, but presenting as early pregnancy losses. The 
signals that end the implantation window make sure that only those embryos 
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that have achieved developmental competency are implanted into the 
endometrium within this restricted period.  
 
1.4.2.3 The window of natural embryo selection 
 
The end of implantation window coincides with decidualisation of the stromal 
compartment which occurs in the mid-late luteal phase of the menstrual cycle 
independently of pregnancy  This functional window in which decidualising 
endometrial stromal cells facilitate maternal identification and rejection of 
developmentally compromised embryos is  named as ‘the window of natural 
embryo selection’ (Teklenburg et al., 2010). Decidualisation also prepares the 
endometrium for deep placentation in pregnancy. Any abnormality in the 
window of natural embryo selection weakens the embryo biosensor quality 
predisposing to miscarriage and recurrent miscarriages. Placental formation is 
also impaired causing obstetric complications such as pre-eclampsia, intra-
uterine growth restriction and preterm delivery (Teklenburg et al., 2010).  
 
1.4.3 Decidualisation of endometrial stromal compartment 
 
The word ‘decidua’ is derived from the Latin ‘decidere’ that means ‘to fall off’. 
The increase in progesterone levels in the luteal phase of the menstrual cycle 
allows extensive modifications in the endometrium by secretory transformation 
of the endometrial glands, and by facilitating the differentiation of stromal cells 
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that involves morphological and biochemical transformation of elongated, 
spindle-shaped stromal fibroblasts into rounded, secretory, epitheloid like 
decidual cells that acquire myofibroblastic function (Gellersen and Brosens, 
2003). It inhibits the proliferation of endometrial epithelium and generates 
vascular remodelling characterised by development and coiling of spiral arteries 
and growth of subepithelial capillary plexus (Gambino et al., 2002). Influx of 
immune cells occurs mainly by the uterine natural killer cells (uNK cells) and to 
some effect of macrophages and T cells (Bulmer et al., 1991). The stromal cells 
increase in size by at least five times and their identification based on their 
morphology becomes easy with their peculiar appearance of pale staining 
cytoplasm with an open vesicular nucleus on staining with haematoxylin and 
eosin (King, 2000). This well-designed remodelling of the endometrium allows it 
to transiently acquire a receptive phenotype. The initiation of decidualisation of 
the stromal compartment occurs in response to elevated progesterone and 
increasing levels of cellular cyclic-AMP (Gellersen and Brosens, 2003), and a 
continuous progesterone signalling is required for the maintenance of a 
receptive phenotype. Successful implantation guarantees persistently raised 
progesterone levels, which ensure decidual survival and integrity during 
trophoblast invasion and placenta formation (Brosens and Gellersen, 2006). 
 
The process of differentiation originates in the stromal cells that surround the 
terminal portion of the spiral arteries (Streeter’s columns) during the mid-
secretory phase of the cycle (de Ziegler et al., 1998). Decidualisation eventually 
spreads to encompass the entire superﬁcial endometrial layer by the late luteal 
phase of the cycle (Teklenburg et al., 2010), and in pregnancy it spreads to the 
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basal layer which is crucial for trophoblast invasion, and in formation of the 
placenta (Brosens et al., 2002). The stromal cell differentiation induces 
expression of several proteins, cytokines, growth factors and neuropeptides that 
promote endometrial receptivity. The forkhead box protein (FOXO1) is 
significantly induced upon decidualisation and is a key regulator of 
decidualisation (Gellersen and Brosens 2003). FOXO1 is instrumental for the 
expression of various phenotypic markers that include prolactin (PRL), insulin-
like growth factor binding protein – 1 (IGFBP-1), left-right determination factor 2 
(LEFTY2), wingless-type MMTV integration site family, member 4 (WNT4) and 
WNT16 (Takano et al., 2007). The first two are commonly used as phenotypic 
markers of decidualisation. 
      
 
 
Figure 1.1: The functional windows of the menstrual cycle essential for reproduction. 
The likelihood of conception is determined by highly coordinated changes in the cycling 
endometrium, which at a functional level are deﬁned as the fertile window, the 
implantation window and the functional window of natural embryo selection. Every 
cycle either leads to menstruation (≈ 400 times in a woman’s lifetime) or to pregnancy 
(≈ 2 times in a woman’s lifetime). (with permission from Oxford Journals: Teklenburg et 
al., (2010) The molecular basis of recurrent pregnancy loss: impaired natural embryo 
selection. Mol Hum Reprod. 16(12):886-95.) 
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1.4.3.1 Decidualisation: Endometrial receptivity and Biosensors of 
embryo quality 
 
The process of decidualisation in humans, which is initiated in the mid to late 
luteal phase of the menstrual cycle, is regulated under maternal control 
regardless of a pregnancy or implantation (Teklenburg et al., 2010a). The 
spontaneous, cyclical decidual transformation is essential for humans which 
enable the endometrium to transiently achieve a receptive phenotype. The 
endometrial response to individual embryos varies and depends on embryo 
quality (Figure 1.2). The decidualising endometrial stromal cells (ESC) acquire 
an incredible competence to reply to individual embryonic signals upon 
implantation and to function as ‘bio-sensors’ (Teklenburg 2010b), which serves 
as a mechanism for maternal recognition, prompt rejection and disposal of 
compromised embryos.  
 
The in-vitro studies undertaken by Teklenburg et al. (2010b) to recognize the 
vital factors of implantation used a human co-culture model of decidualising 
stromal cells and hatched blastocysts. They elegantly demonstrated that out of 
the 14 secreted cytokines, chemokines and growth factors associated with 
implantation, the arresting embryo triggered a strong inhibitory response to 
eight factors. This suggests that the decidualising stromal cells react to a 
morphologically poor quality embryo by closing down the secretion of key 
implantation factors. However, a developmentally competent embryo caused no 
significant alteration in the secretions of implantation mediators from the 
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decidualising ESCs, except for a modest reduction in the expression of 
interleukin-5 levels. The blastocysts, irrespective of embryo quality, made no 
difference to the secretion of implantation factors when co-cultured with 
undifferentiated ESCs. 
 
 
 
Figure 1.2: Decidual transformation of human endometrial stromal cells in vivo and in 
vitro. (A) Decidualization of the stromal compartment (arrow-heads) is initiated during 
the mid-secretory  phase of the cycle in stromal cells that surround the terminal portion 
of the spiral arteries (left panel) and then spreads to encompass the entire superﬁcial 
endometrial layer by the late luteal phase of the cycle (right panel). (B) Phalloidin 
staining of ﬁla- mentous actin in undifferentiated and decidualized primary endometrial 
stromal cells in culture (left and right panels, respectively) highlights the phe- notypic 
reprogramming of the cells that underpins their very diverse functions. Decidualization 
is characterized by a dramatic increase in ﬁlamentous actin polymerization and stress 
ﬁbre formation (red staining). The nuclei were stained with 4’,6-diamidino-2-
phenylindole (blue stain). (with permission from Oxford Journals: Teklenburg et al., 
(2010) The molecular basis of recurrent pregnancy loss: impaired natural embryo 
selection. Mol Hum Reprod. 16(12):886-95.) 
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1.4.3.2 Impaired endometrial decidualisation and reproductive 
failures. 
 
If decidualisation of the stromal compartment is critical for endometrial 
preparation for a successful pregnancy, it is acceptable to envisage that 
impaired decidualisation causes adverse pregnancy outcomes. The evidence 
from population based studies denotes that any perturbations in endometrial 
receptivity and natural embryo selection increase the risk of early pregnancy 
problems. A cohort study by Wilcox et al. (1999) examined from daily first 
morning urine samples from 221 women with no fertility problems, but trying to 
conceive, for markers of ovulation (estrone 3-glucuronide and pregnanediol 3-
glucuronide) and hCG as a marker for implantation. They demonstrated that in 
successful pregnancies, implantation occurred 8 to 10 days post-ovulation, 
whereas a dramatic increase in early pregnancy losses was noted when the 
implantation occurred beyond the window of implantation. Jukic et al., (2011) 
found that late implantations were more likely to be associated with early 
pregnancy losses and to a lesser extent with surviving conceptions. 
 
Biological evidence for endometrial dysfunction associated with early pregnancy 
failure originates from histological evaluation of the peri-implantation 
endometrium using traditional dating criteria (Noyes et al., 1950). Two 
morphological studies that followed strict criteria for comprehensively 
investigating for RMC and in obtaining a timed endometrial biopsy, reported that 
17.4 - 27% of women with RMC were found to have delayed peri-implantation 
61 
 
endometrial development (Tulppala et al., 1991; Li et al., 2000). It was found 
that 60% of the biopsies from women with RMC had restricted endometrial 
development (Serle et al., 1994) when a morphometric analysis, a quantitative 
analysis of the changes involving different endometrial components, of the 
endometrium was undertaken. Studies have attempted to measure the 
concentrations of secretory proteins from the uterine flushing of women with 
RMC. These secretory proteins reflect the secretory activity of the endometrial 
glands and of the epithelium. Two important proteins, MUC1 and placental 
protein 14 (PP14) or glycodelin, are found to be reduced in women with RMC 
(Hey et al., 1994; Dalton et al., 1995; Salim et al., 2007).   
 
The in-vitro experiments on decidualising ESCs provide further evidence on the 
impaired endometrial receptivity and poor reproductive outcome, particularly 
RM. Salker et al. (2010) measured the expression of two marker genes in the 
decidualising ESCs - Prokineticin-1 (PROK 1) and PRL. PROK1 is a vital 
cytokine which regulates endometrial receptivity via induction of leukaemia 
inhibitory factor in endometrial epithelial cells and PRL is a marker for 
decidualisation. They found that significantly higher levels of PROK-1 and 
markedly low levels of PRL were demonstrated in the decidualising ESCs from 
women with RM when compared to controls. These findings are suggestive of 
an intrinsic impairment of endometrial decidual transformation and uterine 
receptivity in women with RM. 
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Endometrial gene expression studies using microarray analysis of the 
endometrial biopsies obtained in the implantation window provide detailed 
information on endometrial receptivity. Many genes that are involved in distinct 
biological functions of cellular signalling (by inhibition and degradation of cyclic-
AMP and abnormal calcium metabolism), cellular function and maintenance 
(lymphocyte homeostasis), nucleic acid metabolism and small molecule 
biochemistry are differentially expressed at the time of endometrial receptivity in 
women with RM. In RM, the humoral immune response and organ and muscle 
development are highly differentially regulated when compared to fertile controls 
(Lédée et al., 2011). 
 
SGK1, a serine-threonine protein kinase, is induced by an increase in 
progesterone levels and executes an important role in cellular stress response. 
SGK1 is found initially in the luminal epithelial cells and then in the decidualising 
ESCs and plays a crucial role in early pregnancy (Feroze-Zaidi et al., 2007). 
Salker et al., (2011) found that the mid-secretory endometrial SGK1 transcript 
levels in women with RMC were markedly lower, when compared to fertile 
controls by day 4 of differentiation in cell cultures. They also demonstrated in 
immunohistochemical studies that phosphorylated SGK1, which reflects 
activated kinase, were lower in the stromal compartment of the endometrium of 
women with RM. In pregnant mice, they found that a lack of SGK1 in the 
decidua did not impair implantation, but was associated with bleeding and 
inflammation at the feto-maternal interface, and other events similar to obstetric 
complications such as miscarriage, growth restriction and stillbirth in humans. 
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Finally, further work by Salker at al. (2012) described that ESCs upon 
decidualisation mount a transient pro-inflammatory response and these signals 
activate the expression of endometrial epithelial receptivity genes followed by 
an anti-inflammatory response which is vital for embryo support. They showed 
that in decidualising ESCs from RMC women, a chaotic auto-inflammatory 
response, occurs as result of deregulated activation of IL-33/ST2L/sST2 
pathways. This protracted anti-inflammatory response causes a prolonged 
implantation window and thereby disables natural embryo selection.   
 
1.4.3.3 Migratory response of decidualised ESCs to embryo quality 
 
Once the blastocyst breaches the luminal epithelium and enters the stromal 
compartment, the trophoblastic shell of the conceptus forms the floating and 
anchoring villi. The extravillous trophoblast (EVT) cells originate from the cell 
columns of these anchoring villi which then enter the decidua and inner third of 
the myometrium (reviewed in Brosens et al., 2002). The terminal spiral arteries 
are infiltrated by a sub-group of EVTs named as endovascular EVTs, which 
plug these vessels for several weeks before displacing the endothelial cells. 
This process also destroys the musculoelastic wall of the spiral arteries and 
thereby creating a low-resistance, high flow utero-placental circulation (Brosens 
and Gellersen, 2010). This invasive nature of EVTs which is intensely regulated 
by decidual cells is indispensable for embryo survival. In-vitro cell culture 
experiments offer intricate evidence on the intercellular cross-talk between the 
decidual and trophoblast cells. When blastocysts placed on a mono-layer of 
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decidualised ESCs in in-vitro co-culture experiments, the stromal cell motility 
increased at the contact zone with the expanding blastocyst and the cells move 
away from the blastocyst (Grewal et al., 2008; Grewal et al., 2010). The stromal 
cells acquire this enhanced migratory and invasive capacity only upon 
decidualisation which is further increased in response to trophoblast derived 
signals (Gellersen et al., 2010). The decidualisation is further augmented by the 
paracrine signals that come from trophoblast secretions and in response 
decidualised ESCs provide a positive environment for trophoblast expansion 
and invasion (Gonzalez et al., 2011). The trophoblast expansion into the 
decidua depends on the migratory capacity of the decidual cells and limiting 
these regulatory pathways that control motility, cyto-skeletal reorganisation and 
focal adhesion severely affect blastocyst expansion (Grewal et al., 2008; 
Grewal et al., 2010). In transwell migration assays, Gellersen et al. (2013) 
demonstrated the reciprocal attraction between decidual cells and the 
trophoblast, and suggested that this migration occurs as a result of active 
signalling between the two. They also revealed that the trophoblast spheroid 
expansion was greater on a monolayer of decidualised ESCs, which is further 
enhanced by a combination of implantation factors when compared to co-
culture of trophoblast with undifferentiated ESCs. Decidual cell motility is 
controlled by various local factors such as heparin binding EGF-like growth 
factor (HB-EGF) and platelet derived growth factor (PDGF)-BB, and 
trophoblast-derived factors such as PDGF-AA and many other chemotactic 
factors yet to be identified (Schwenke et al., 2013).  
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Further in-vitro studies have shown that the decidualised ESCs from fertile 
women adjust their migratory activity in response to the quality of an embryo. 
Weimer et al., (2012) used well designed migration assays to demonstrate the 
migratory response of decidualised ESCs from RM women in the presence of 
trophoblast spheroids of different sizes and day 5 embryos of different 
developmental potential. The ESCs from women with RM more actively 
migrated towards the trophoblast spheroid when compared to ESCs from 
control women. The migration of ESCs from RM women in the presence of a 
developmentally incompetent embryo was significantly more when compared to 
the migration in the absence of an embryo. This migration was comparable to 
the migration of the ESCs from RM women to good quality embryo and also 
from fertile control to good quality embryos (Figure 1.3). These findings 
emphasise the increased migratory responsiveness of the decidualised ESCs 
from RM women towards EVT signals and their inability to differentiate 
developmentally competent embryos from the compromised ones.  
 
To summarise, an effective endometrial transformation is compulsory for a 
successful implantation, which ensures that the stromal compartment acquires 
a receptive phenotype and also enables embryo recognition and selection. 
Failure of the ESCs to express this vital characteristic may lead to rapid 
conceptions, but allows repeated pregnancy failures in keeping with the 
‘selection failure’ hypothesis. The decidual ESCs actively choose a good quality 
embryo for implantation and restrict their migratory activity for a 
developmentally incompetent embryo. The inability of decidual ESCs of RM 
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women to identify and to adjust migratory response to good and poor quality 
embryos may reinforce the concept of an impaired natural selection process. 
 
           
Figure 1.3: The migration zone after adding a high-quality, low-quality or no embryo. 
The migratory response of decidualized H-EnSCs from normally fertile (A–C) and RM 
women (D–F) was analyzed in absence of a human embryo (A and D), in presence of a 
high-quality embryo (B and E) or a low-quality embryo (C and F). Phase contrast 
pictures were taken 18 hours after creating the migration zone. The dotted line 
represents the front of the migration zone directly after its creation. As a reference for 
the position of the embryo, the bottom of the plate was marked. The arrows indicate the 
position of the embryo. All pictures were taken with 25x magnification. (From Weimer et 
al., (2012) Endometrial Stromal Cells of Women with Recurrent Miscarriage Fail to 
Discriminate between High- and Low-Quality Human Embryos. PLoS One 7(7): 
e41424.   
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1.4.4 Endometrial Leucocytes: 
 
Though the fetus inherits both maternal and paternal histocompatibility antigens 
it still does not get rejected by the maternal tissues and this hemi-allogenic fetus 
survives within the maternal uterus as a result of an exceptionally structured 
and a bi-directional immunological association shared by the two. Various key 
factors in the peri-implantation endometrium are likely to play a major role in the 
immune success of normal pregnancy and the major responsibility lies with the 
endometrial leucocytes, which establish maternal immunologic adaptations to 
fetal antigens and by maintaining tissue integrity.  
 
In the proliferative phase, the stratum functionalis of the endometrium has few 
scattered uterine leucocytes, mainly natural killer (uNK) cells, T cells and 
macrophages. These cells account for around 10% of the stromal cells and 
contribute to the majority of immune cell types in the endometrium (Bulmer et 
al., 1991a). Subsets of leucocytes and their phenotypes are mainly identified by 
flow cytometry analysis of surface antigens or by immunohistochemistry. The 
CD45 antigen is common to all endometrial leucocytes. 
 
1.4.4.1 T-cells 
 
The T cell density in the proliferative stage is about 45% of the leucocytes and 
numbers remains the same throughout the secretory phase and in pregnancy 
(Vassiliadou and Bulmer, 1996), but as substantial numbers of uNK cells 
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migrate into the endometrium in the peri-implantation period, the number of T 
cells relatively decrease in number. CD3 is a marker for all T cells that comprise 
both CD4 (T helper) and CD8 (cytotoxic T cell).  
 
CD8+ T lymphocytes are significantly reduced among RM women compared to 
normal controls. Those women with RM who have normal concentration of 
CD8+ cells are subsequently more likely to have successful pregnancies while 
those with abnormal expression have an increased risk of subsequent 
miscarriages (Lachapelle et al., 1996). Quenby et al., (1999) reported that 
endometrial biopsies from women with RM show a significantly increased 
expression of CD4+ positive cells in the pre-implantation endometrium 
compared to fertile controls whereas there is no difference in the concentration 
of CD3+ and CD8+ cells. Those women who had a subsequent miscarriage had 
significantly more CD4+, and CD8+ cells. Several studies have reported no 
difference in decidual CD3+ cells in RMC women when compared to normal 
early pregnancy (Quack et al., 2001). Reduced numbers of CD4+ CD25bright 
regulatory T lymphocytes in the decidua is found in women with unexplained 
RM when compared with controls (Yang et al., 2008). 
 
1.4.4.2 The endometrial macrophages 
 
The macrophages are mononuclear phagocytic cells that are involved in both 
innate and humoral immunity. They have a varied distribution and are present in 
both stromal and epithelial compartments. The macrophage density significantly 
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increases in the late secretory phase of the menstrual cycle and in early 
pregnancy at the site of implantation (Bulmer et al., 1991b). They are the 
second most abundant leucocytes in the endometrium and decidua contributing 
to 20% of all decidual leucocytes (Bulmer et al., 1988). The endometrial 
macrophages are identified by their expression of CD14 and CD68 antigens.  
 
The exact role of macrophages in the peri-implantation endometrium is not fully 
understood. It is thought that they may play a role in apoptosis of unwanted 
cells and clearing up of cell debris to maintain cellular homeostasis during 
implantation (reviewed in Mor and Abrahams, 2003). In-vitro studies suggest 
that macrophages are in close proximity to spiral arteries and they may have a 
role in the regulation of trophoblast invasion and transformation of spiral 
arteries, but their exact in-vivo function remains unknown (reviewed in Bulmer 
et al., 2010). A recent study by Li et al. (2009) demonstrated that the HLA-G 
homodimer induced the production of potential pro-inflammatory cytokines such 
as IL-6, IL-8 and TNF-α from macrophages and uNK cells. A larger secretion of 
these cytokines was from macrophages and this observation reinforces the role 
of macrophages in spiral artery remodelling. Macrophages can also produce 
macrophage colony stimulating factor, granulocyte colony stimulating factor and 
TNF-α.  
 
There are not many studies that have looked at the association between 
decidual macrophages and RM, the focus being mainly on uNK cells. Quenby et 
al. (1999) reported an increase number of macrophages in luteal phase 
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endometrium whereas Quack et al. (2001) did not find any differences in the 
macrophages between RM women and controls. 
 
1.4.4.3 The uterine natural killer cells 
 
uNK cells are the most abundant leucocytes in the decidual stroma and account 
for 70-80% of the decidual leucocyte population. The uNK cells are large 
lymphocytes (~45 µm diameter) with prominent cytoplasmic granules which 
contain lytic proteins and with a kidney shaped nucleus. They are also known 
as uterine large granular lymphocytes. The uNK cells are identified by their 
expression of CD56 antigen at high concentration (CD56bright) and lack CD16, 
which is found on the most peripheral NK cells. Thus they are CD56bright CD16- 
in distinction to the most of the peripheral blood NK cells which are 
CD56dimCD16+ (Starkey et al., 1988). A subgroup of peripheral NK cells has a 
similar phenotype as uNK cells (CD56bright CD16-), but a large majority are 
CD56bright CD16+ (Lanier et al., 1983). The uNK cell density significantly 
increases following ovulation and continues to increase until a few days before 
menstruation (King et al., 1989). The uNK cells peak in density in the first 
trimester of pregnancy (Starkey et al., 1998).  
 
The changes in the immune environment in the endometrium are thought to be 
equally important as compared to stromal decidualisation for a successful 
implantation and maintenance of pregnancy. In humans, the decidual process 
creates maternal immunologic tolerance to fetal antigens, thereby ensuring 
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protection of conceptus. Differentiating endometrial stromal cells have a 
function to regulate different immune cell density in the peri-implantation period 
and cause an influx of macrophages and uNK cells. The decidual stromal cells 
secrete interleukins (IL-11 and IL-15), which cause proliferation and 
differentiation of uNK cells in the decidualising stromal compartment (Dimitriadis 
et al., 2005). 
 
The actual function of these uNK cells around implantation and early pregnancy 
remains debated and numerous questions on their origin and function continue 
to be unanswered. Previously, it was thought that they might facilitate 
implantation of the blastocysts, including those with aneuploidy and thus 
contributing to early pregnancy failures. There is now a good body of evidence 
to suggest that uNK cells are involved in promoting decidualisation and are 
involved in regulating fetal trophoblast invasion by their production of crucial 
cytokines, chemokines and growth factors such as IL-8, IP-10, TNF-α, TGF-β1 
and IFN-γ (reviewed in Bulmer et al., 2010). They also induce angiogenesis and 
vascular remodelling in the decidua by their ability to secrete an array of 
angiogenic growth factors (Hanna et al., 2006).  Appropriate development and 
maintenance of decidua and maternal arteries is impaired in mice when uNK 
cells are absent from the peri-implantation endometrium. The uNK cell deficient 
mice have decidual cell degeneration, endothelial cell alteration (Greenwood et 
al., 2000) and poor spiral arteries (van den Heuvel et al., 2005).  
 
Kuroda et al. (2013) demonstrated that decidualisation was associated with a 
significant induction of 11-β hydroxysteroid dehydrogenase type 1 enzyme 
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(11βHSD1), that catalyses the conversion of inactive cortisone to active cortisol, 
in a time-dependent manner. Inhibition of 11βHSD1 decreases cortisol 
synthesis and thus selectively affects expression of decidual marker genes. 
This defective decidualisation was found to be associated with women with a 
high uNK cell density of more than five percent in the peri-implantation 
endometrium as assessed by immunohistochemical methods.  
 
Recruitment and proliferation of leucocytes in the endometrium is an important 
transformation that occurs as a part of decidualisation and altered uNK cell 
function and density has been proposed to play a major role in reproductive 
failures. Many studies have found an increased uNK cell density in the 
endometrium of women with RM (Lachapelle et al., 1996; Quenby et al., 1999, 
2005, 2009; Tuckerman et al., 2007). A systematic review suggested no 
conclusive evidence of high levels of uNK cells in predicting subsequent 
miscarriage in women with idiopathic RM (Tang et al., 2011). Quenby et al. 
(2005), in their prospective study investigated the effects of steroids on uNK 
cells and successfully demonstrated a marked decrease in the uNK cell density 
in women with RM after three weeks of treatment with prednisolone. A pilot 
double blind randomised controlled trial designed to assess the feasibility of 
screening women with idiopathic RM for high uNK density and randomising to 
prednisolone or placebo found an increase in live birth rate and decrease in 
miscarriage in the prednisolone group when compared to placebo group, (LBR: 
RR 1.5, 95% CI 0.8-2.9 and for miscarriage RR 0.67, 95% CI 0.4 – 1.3) (Tang 
et al., 2013). In this trial, women with very high uNK density of more than ten 
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percent appeared to have the worst outcome when compared to those with uNK 
cell density of five to ten percent.    
 
In summary, the immune system plays a dominant role in the normal biology of 
human endometrium. The recruitment and proliferation of uNK cells depends on 
effective decidualisation and high uNK density is associated with perturbed 
decidualisation. Though decidualisation causes influx of uNK cells into the 
endometrium, their appropriate regulation is vital as high density uNK cells in 
the peri-implantation endometrium appears to contribute to pregnancy 
complications including RM. Steroid treatment has been shown to be beneficial 
in reducing the uNK cell density. The role of other leucocytes in decidualisation 
and implantation remain unclear.    
 
1.4.5 Endometrial mesenchymal stem cells 
 
Spontaneous endometrial stromal decidualization is an outstanding feature in 
humans, shared with only a few other mammalian species, and is also 
responsible for the menstrual shedding of the endometrium in the absence of a 
pregnancy. The human endometrium has remarkable regenerative capacity 
(Gargett et al., 2012) and with an ability to grow to 5-7 mm thickness from an 
initial 0.5-1 mm just after menstruation (McLennon and Rydell, 1965). The 
endometrium cyclically proliferates, differentiates, sheds and then regenerates 
in response to ovarian steroids for about 400 times in a woman’s reproductive 
lifespan (Jabbour et al., 2006; Brosens and Gellersen, 2006). Endometrial 
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regeneration also occurs following resection of the endometrium after 
pregnancy and in women taking hormone replacement therapy after 
menopause (Gargett. 2006; Gargett. 2007). Adult stem cells, derived from 
postembryonic cell lineages and with their ability of cellular production, are 
present in highly regenerative bone marrow, the epidermis and intestinal 
epithelium are responsible for a new tissue growth in these organs (reviewed in 
Gargett and Masuda, 2010). The adult stem cells have an important role in 
maintaining tissue homeostasis by providing replacement cells lost through 
cellular turnover and following tissue damage (Gargett and Healy, 2011). These 
adult stem cells that are identified in the stratum basalis of the endometrium do 
not differ between phases of the menstrual cycle and are also present in the 
atrophic endometrium of post-menopausal women and in inactive endometrium 
of women taking hormonal contraceptive pills (Schwab et al., 2005). Gargett 
and Masuda, (2010) reviewed the available evidence on eMSCs and found that 
the endometrial stroma harbour undifferentiated multipotent eMSCs which are 
phenotypically and characteristically similar to the ones found in bone marrow 
and adipose tissue, but they are absent in other reproductive tissues such as 
myometrium, Fallopian tubes and uterosacral ligaments.      
  
The origin of these stem cells in the endometrium remains unanswered. It is 
possible that the eMSCs are derived from residual fetal stem cells (Gargett, 
2007), but there is also some evidence to suggest that bone marrow-derived 
cells may also add to the pool of resident adult stem cells in the endometrium 
(Ikoma et al., 2009). In mouse studies, Du and Taylor (2007) have 
demonstrated that the stem cells derived from the bone marrow are present in 
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the endometrium. Using a transgenic mouse, Bratincsak et al., (2007) showed 
that CD45- positive haematopoietic stem cells are present in the endometrial 
epithelium, which are responsible for contributing to more than eighty percent of 
the endometrial epithelial cells in pregnancy.  eMSCs are a subpopulation of 
pericytes found in the peri-vascular regions of the endometrial stroma, both in 
the basalis and functionalis layers (Schwab and Gargett, 2007). 
 
Clonogenecity, the ability of single cells to form colonies when plated at very 
low densities, has traditionally been used to characterize stem cells populations 
derived from multiple adult tissue types (Chan et al., 2004). 
 
Cancer stem cells, which are identical to adult stem cells in their key properties, 
but not in function as they are not regulated by the stem cell niche (Pardal et al., 
2003) – anatomic structure where adult stem cells reside (Li and Xie, 2005), are 
implicated in breast cancer, acute myeloid leukaemia, prostate cancer, 
glioblastoma and endometrial cancer (Pardal et al., 2003; Kato et al., 2008; 
Hubbard et al., 2009). The eMSCs are also associated with the development of 
endometriosis (reviewed in Sasson and Taylor, 2008) and adenomyosis (Chen 
et al., 2010). MSCs, particularly the bone marrow derived ones, are a well-
established source of cells in regenerative medicine and are increasingly being 
used in clinical trials for the treatment of heart disease, stroke, cartilage repair 
and spinal cord injury (reviewed in Gargett and Masuda, 2010). 
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1.5 Project hypotheses and objectives: 
 
In this thesis, to explore the effects of obesity on the endometrium, I 
hypothesise the following: 
 
1. Obese women have an increased risk of first trimester miscarriage and 
the pregnancy loss pattern is different in obese women when compared 
to normal weight women as a result of the negative effects of obesity. 
 
2. Obese women with recurrent miscarriage have a significantly shorter 
time to pregnancy when compared to normal weight women with 
recurrent miscarriage secondary to perturbations in the peri-implantation 
endometrial development.  
 
3. The leucocytes density in the peri-implantation endometrium, the 
immune cells which are likely to play a role in reproductive success, is 
significantly different in obese women when compared to that of normal 
weight women. 
 
4. The abundance and clonogenic efficiency of endometrial mesenchymal 
stem-like cells, which play an important role in endometrial regeneration, 
are impaired in the peri-implantation endometrium of obese women. 
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5. The decidual programming of the peri-implantation endometrium, an 
essential transformation for a successful implantation, is perturbed in an 
obesogenic environment. 
 
In order to study my hypotheses, I set out the following specific objectives: 
 
1. To evaluate the early pregnancy reproductive outcome of women who 
attended a tertiary referral Implantation Clinic with various reproductive 
failures, particularly looking at early pregnancy loss patterns in obese 
women comparing them to normal and overweight women.  
 
2. To analyse pregnancy loss pattern and time to pregnancy intervals in 
obese women with recurrent miscarriage and compare them to normal 
weight women with recurrent miscarriage. 
 
3. To define the peri-implantation endometrium in obese women and 
compare it to normal weight women, particularly looking at: 
a. The sub-epithelial uterine natural killer cell and macrophage density 
by immunohistochemical studies. 
b. Endometrial mesenchymal stem cell density and function using 
magnetic beads separation and in-vitro colony-forming assay 
c. In-vitro endometrial stromal cell differentiation and analysis of 
decidual markers expression in artificial obesogenic environment  
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CHAPTER 2: 
SUBJECTS, MATERIALS AND METHODS 
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2.1 Ethical approval 
 
This research was conducted at and supported by Biomedical Research Unit in 
Reproductive Health, a joint initiative between University Hospitals of Coventry 
and Warwickshire NHS Trust and the University of Warwick. Ethical approval for 
this study was obtained from the National Research Ethics - Hammersmith and 
Queen Charlotte’s Hospital Research Ethics Committee (1997/5065) and the 
research sponsorship for this study has been transferred from Imperial College, 
London to the University of Warwick. The study has also been approved by the 
University Hospitals Coventry and Warwickshire Research and Development 
department, and written informed consent was obtained from all participants, in 
accordance with the guidelines in The Declaration of Helsinki 2000. 
 
2.2 Patient selection: 
 
The subjects were recruited for the study from the tertiary referral Implantation 
clinic, a dedicated endometrial research clinic at the Centre for Reproductive 
Medicine, University Hospitals of Coventry and Warwickshire NHS Trust for 
women with recurrent miscarriage or recurrent IVF treatment failure. The 
women were either referred from IVF and recurrent miscarriage clinics around 
the United Kingdom or the women contacted the clinic directly. At the initial 
consultation, the medical history that included details of previous pregnancy 
outcome for each pregnancy and details of time to pregnancy intervals was 
recorded by a medical staff from these women. The early pregnancy losses 
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(EPL) in the first trimester were classified as (i) Biochemical pregnancies losses 
(BPL): where the pregnancy was diagnosed by either serum or urine b-hCG 
without an ultrasound evaluation and the serial results suggesting a pregnancy 
loss, (ii) Empty gestational sac losses (EGSL): where an intra-uterine 
pregnancy sac was visualised on ultrasound with or without yolk sac, but 
without an embryo (iii) Fetal losses (FL): where an intrauterine pregnancy was 
demonstrated on ultrasound, with an embryo, but without cardiac activity or at 
least two ultrasound scan assessments with at least 7 days difference 
suggesting intrauterine pregnancy with an embryo, but with no cardiac activity, 
(iv) Recurrent miscarriage (RM): three or more consecutive pregnancy loss less 
than 24 weeks of gestation.  
 
All subjects who attended the clinic underwent anthropometric measurements 
and the BMI or Quetelet index was calculated using the standard definition of 
“weight in kilogrammes divided by the square of height in meters”. The WHO 
classification was used to categorize women into three groups: Normal (BMI: 
19.0 – 24.9 kg/m2), Overweight (BMI: 25 – 29.9 kg/m2) and Obese (BMI ≥ 30 
kg/m2). 
 
The women who underwent endometrial biopsy were advised to use ovulation 
prediction kits to detect a surge in LH and were instructed to contact the clinic 
co-ordinator for an appointment 5 to 10 days after the pre-ovulatory LH surge. 
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2.3 Endometrial sampling: 
 
The endometrial biopsies were obtained from patients in the peri-implantation 
period, 5 to 10 days after the pre-ovulatory LH surge. The procedure was 
explained to the women and a written informed consent was obtained in 
accordance with the guidelines in The Declaration of Helsinki, 2000. They were 
also warned of possible cramp-like lower abdominal pain during and after the 
procedure and that some may experience vaginal spotting or bleeding.  
 
A trans-vaginal ultrasound scan was carried out to identify the uterine shape, 
size, version, endometrial thickness and to rule out any uterine and endometrial 
pathology. The women were placed on an examination table with feet and legs 
supported as for a pelvic examination. The cervix was visualised using a bi-
valve, self-retaining Cusco’s speculum. A disposable endometrial sampler 
(Wallach EndocellTM sampler, Wallach Surgical Devices Inc., Trumbull, USA) 
was gently introduced into the uterine cavity until the fundus was reached. A 
tenaculum or vulsellum was used to the upper lip of the cervix to steady the 
cervix and uterus if a difficulty was encountered at initial insertion of the 
endometrial sampler. The inner piston of the sampler was drawn back creating 
suction and the endometrial sample was obtained starting from the fundus and 
moving downwards to the internal cervical ostium, rotating it while being 
removed from the cavity. One half of the sample was fixed in 4% 
paraformaldehyde in phosphate buffered saline (PBS) at pH 7.4 for 24 to 48 
hours, then processed in a tissue sampler overnight and embedded in paraffin 
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for immunohistochemistry. The other half of the sample was placed in 
Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F12, Life 
Technologies Ltd., Paisley, UK) and transported immediately to the laboratory 
for isolation of primary human endometrial stromal cell culture.  
 
For some women it was difficult to obtain the endometrial biopsy sample in the 
clinic and they underwent a diagnostic hysteroscopy and endometrial biopsy 
under a general anaesthetic. 
 
2.4 Immunohistochemistry: 
 
2.4.1  Materials: 
 
1. Adhesive microscope slides - Leica Xtra® adhesive slides, Leica 
Microsystems (UK) Ltd, Milton Keynes, UK  
2. Distilled water  
3. Hematoxylin (<0.1%) - Leica Microsystems (UK) Ltd, Milton Keynes, UK  
4. Isopropyl alcohol (IPA) – 100%, 90% and 70% 
5. Novocastra™ Protein Block - 0.4% Casein in phosphate-buffered saline, with 
stabilizers, surfactant, and 0.2% Bronidox L as a preservative, Leica 
Microsystems (UK) Ltd, Milton Keynes, UK  
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6. Novolink™ Polymer (Anti-rabbit Poly-HRP-IgG (<25μg/mL) containing 10% 
(v/v) animal serum in tris-buffered saline/0.09% ProClin™ 950) - Leica 
Microsystems (UK) Ltd, Milton Keynes, UK  
7. PAP hydrophobic pen - abcam®, Cambridge, UK  
8. PickCell 2100 steam antigen retrieval unit - PickCell Laboratories, Leiden, the 
Netherlands 
9. Phosphate buffered solution (PBS)  
10. Post-primary (Rabbit anti mouse IgG (<10 μg/mL) in 10% (v/v) animal 
serum in tris-buffered saline/0.09% ProClin™ 950) - Leica Microsystems (UK) 
Ltd, Milton Keynes, UK 
11. Primary antibody (Monoclonal Mouse anti-Human CD56 clone 123C3) - 
Dako UK Ltd, Ely, Cambridgeshire, UK 
12. Primary antibody (Novocastra™ Lypholized Mouse Monoclonal antibody 
CD14) - Leica Microsystems (UK) Ltd, Milton Keynes, UK 
13. Rotary Microtome - Leica RM 2235, Leica Microsystems (UK) Ltd, Milton 
Keynes, UK 
14. Sodium citrate antigen retrieval solution - Leica Microsystems (UK) Ltd, 
Milton Keynes, UK 
15. Tris-buffered saline plus 0.05% tween20 (TBST) 
16. Xylene 
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17. 3% (v/v) hydrogen peroxide - Leica Peroxidase Block, Leica Microsystems 
(UK) Ltd, Milton Keynes, UK  
18. 3, 3’ – diaminobenzedine (DAB) (prepared from DAB Chromogen: 1.74% 
w/v 3,3’ - diaminobenzidine, in a stabilizer solution and Novolink™ DAB 
Substrate Buffer (Polymer): Buffered solution containing ≤0.1% hydrogen 
peroxide and preservative) - Leica Microsystems (UK) Ltd, Milton Keynes, UK 
 
2.4.2 Slide preparation 
 
The endometrial sample was fixed in 4% paraformaldehyde in PBS at pH 7.4 for 
24 to 48 hours, then processed in a tissue sampler overnight and embedded in 
paraffin. 3 microns thick sections of the paraffin embedded biopsies were cut on 
a rotary microtome. The sections were floated in a warm water bath (450C) 
before being picked up onto adhesive microscope slides and allowed to drain. 
The slides were placed into an oven at 650C for a minimum of an hour, 
preferably overnight, to ensure sections adhere to slides. De-waxing of the 
paraffin sections was done by placing them into staining vessels containing 
Xylene for 5 minutes, twice, then twice in 100% IPA for 5 minutes each, in 90% 
IPA for 5 minutes, in 70% IPA for 5 minutes and finally in Distilled Water for 5 
minutes. The sections were placed in optimal pH buffer (Sodium citrate antigen 
retrieval solution, buffer pH 6) for antigen retrieval in PickCell 2100 steam 
antigen retrieval unit for 2 hours. Margins were drawn on either end of the slide, 
bracketing tissues, using a PAP hydrophobic pen to limit the amount of 
reagents used. 
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The sections were washed twice with TBST for 5 minutes each time. 
Endogenous peroxidase activity was blocked using 3% (v/v) hydrogen peroxide 
for 10 minutes. The sections were washed twice with TBST for 5 minutes each, 
followed by incubate in Novocastra™ Protein Block for twenty minutes to an 
hour to reduce non-specific binding of primary and polymer. 
 
2.4.3 Staining for CD56/CD14 antigens: 
 
Primary antibody was applied to the above prepared slides in a dilution of 1/250 
and kept overnight at 40 C or at room temperature for 1 hour. The slides washed 
twice with TBST for 10 minutes and secondary antibody was applied for 30 
minutes at room temperature to detect mouse antibodies. The slides were 
washed twice with TBST for 5 minutes and a polymer (Novolink™ Polymer) was 
applied for 30 minutes at room temperature which recognizes rabbit 
immunoglobulins, post-primary and any tissue bound rabbit primary antibodies. 
The sections were then washed twice in TBST for 5 minutes and incubated with 
DAB for 7 minutes. Reaction with the peroxidase produces a visible brown 
precipitate at the antigen site. The slides were then washed in distilled water for 
5 minutes and haematoxylin was applied for 30 seconds to a minute for 
counterstaining. The slides were then rinsed in distilled water and washed in 
TBST for 5 minutes to blue up haematoxylin. The cells were dehydrated and 
mounted. 
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2.4.4 Analysis and interpretation of the slides: 
 
The images were processed and viewed using ‘Panoramic Viewer’ (3D Histech 
Ltd, Budapest, Hungary). The pictures were captured at 40 x magnification in 5 
randomly selected high power fields and the subepithelial region, avoiding 
glandular areas, were analysed for uterine leucocyte (uNK cell or macrophage) 
density. The blue stained stromal cells and brown stained uNK cells (CD56+)  
and macrophages (CD14+) were counted using the software ‘ImageJ’ and ‘point 
picker plug-in tool’ (National Institutes of Health, Bethesda, MS, USA). An 
average of 500 cells per high power field and hence approximately 2500 cells 
were counted from an endometrial biopsy. The cell density was calculated using 
the formula total number of uterine leucocytes divided by total number of 
stromal cells and then multiplied by 100. 
 
2.5 Endometrial mesenchymal stem-like cell isolation and 
cloning efficiency 
 
2.5.1 Materials: 
Antibiotic-antimycotic solution (1%) - Invitrogen, Paisley, UK 
Anti-PE MicroBeads - Miltenyi Biotec. Bisley, UK 
Basic fibroblast growth factor - Merck Millipore, Watford, UK 
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Cell strainer (100 µm and 40 µm) - Fisher Scientific, Loughborough, UK 
Collagenase (0.5mg/ml) - Sigma-Aldrich, Gillingham, UK 
Deoxyribonuclease type I (0.1mg/ml) - Roche, Burgess Hill, UK  
Dextran-coated charcoal-treated fetal bovine serum (DCC-FBS) (10%) 
Distilled water 
DMEM/F-12 medium - Invitrogen, Paisley, UK 
Estradiol - Sigma-Aldrich, Gillingham, UK 
Ficoll-Paque PLUS - GE Healthcare, Little Chalfont, UK 
Fibronectin (10ug/ml in PBS) 
Haematoxylin 
Insulin - Sigma-Aldrich, Gillingham, UK 
L-glutamine - Invitrogen, Paisley, UK 
MACS separator - Miltenyi Biotec. Bisley, UK 
Magnetic Bead Buffer: containing phosphate buffered saline (PBS), pH 7.2, and 
0.5% bovine serum albumin (BSA) by diluting MACS® BSA Stock Solution 1:20 
with autoMACS® Rinsing Solution  - Miltenyi Biotec, Bisley, UK. 
MS columns - Miltenyi Biotec. Bisley, UK  
Phycoerythrin (PE) conjugated Anti-SUSD2 (W5C5) antibody - BioLegend, 
London, UK 
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2.5.2 Isolation of single cell suspensions of endometrial stromal 
cells:   
 
The endometrial tissue was collected on a petri-dish, washed in DMEM/F-12 
medium and the fluid around the tissue was removed completely. The 
endometrial tissue was finely minced using a sterile blade for 5 minutes and 
enzymatically digested with collagenase (0.5mg/ml) and deoxyribonuclease 
type I (0.1mg/ml) in 10ml of 0% medium (DMEM/F-12 without DCC, L-glutamine 
and antibiotics) for 1 hour at 37oC. The dissociated cells were filtered through a 
sterile 100µm cell strainer on 50 ml tube to remove large undigested tissue and 
then through a 40µm cell strainer to remove glandular clumps. Most of the 
stromal cells and blood cells, present as a single cell suspension, passed 
through the cell strainer, whereas the undigested fragments, mostly comprising 
of glandular clumps, were retained on the strainer. 10ml of 10% culture medium 
(DMEM/F-12 with 10% DCC-FBS, 1% L-glutamine, 2 µg/ml insulin, 1nM 
estradiol and 1% antibiotic-antimycotic solution) was added onto the cell 
strainer and centrifuged at 1200rpm for 5 minutes. The stromal cell pellet was 
resuspended in 8 ml of 10% culture medium. 
 
Stromal single cell suspensions were then layered over Ficoll-Paque PLUS to 
produce two layers and centrifuged at 1500rpm for 15 minutes to remove 
erythrocytes. The cells at the medium/Ficoll-Paque PLUS interface, mainly 
containing stromal cells, were carefully aspirated by pipetting, washed twice 
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with 10% culture medium, centrifuged at 1200rpm for 5 minutes to remove 
some Ficoll-paque, and then subjected to magnetic bead separation.  
 
2.5.3  Magnetic cell separation: 
 
Magnetic bead separation was performed according to the manufacturer’s 
instruction (Miltenyi Biotec, Bisley, UK). Freshly isolated endometrial stromal 
cell number was determined and the cell suspension was centrifuged at 
1200rpm for 5 minutes followed by aspiration of the supernatant. The cell pellet 
was resuspended in Magnetic Bead Buffer (up to 1×106 cells/100µl) and then 
was incubated with PE conjugated Anti-SUSD2 (W5C5) antibody (5µl/1×106 
cells) on ice in the dark for 20 minutes. The cells were washed by adding 1ml of 
Magnetic Bead Buffer per 107 cells and centrifuged at 1200 rpm for 5 minutes to 
remove unbound primary antibodies. Then cell suspensions (up to 1×107 
cells/80µl of Magnetic Bead Buffer) were incubated with Anti-PE MicroBeads 
(20µl/1×107 cells) on ice in the dark for 20 minutes. The cells were washed by 
adding 1ml of Magnetic Bead Buffer per 107 cells and centrifuged at 1200 rpm 
for 5 minutes at 40 C. The cell suspensions (up to 1×108 cells/500ul of Magnetic 
Bead Buffer) were applied onto the MS columns in a magnetic field (MACS 
separator), followed by washing with 500ul of Magnetic Bead Buffer three times. 
While most unlabelled (W5C5-) cells passed through the column, magnetically 
labelled W5C5+ cells were mostly retained on the column. The columns were 
removed from the magnetic field and W5C5+ cells were flushed out by firmly 
pushing the plunger with 1ml of Magnetic Bead Buffer. The magnetic cell 
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separation steps were repeated using a new MS column to increase the purity 
of the magnetically labelled cells. 
 
2.5.4  In-vitro colony forming unit (CFU) assay: 
 
60mm culture dishes were coated with 2 ml of fibronectin for at least 20 
minutes. The excess fibronectin was removed and replaced with growth 
medium containing DMEM/F12 containing 10% DCC-FBS, 1% L-glutamine, 1% 
antibiotic-antimycotic solution, insulin (2µg/ml), estradiol (1nM) and basic 
fibroblast growth factor (10ng/ml). Freshly isolated W5C5+ and W5C5- cells 
were seeded onto culture dishes at a clonal density of 50 cells/cm2 per each 
sample. The first medium change was after the first 7 days. Subsequently, 
media was changed twice in the next week. Colonies were monitored 
microscopically to ensure that they were derived from single cells. Cultures 
were terminated at 15 days, washed thrice in PBS and were fixed in 10% 
formalin (4% formaldehyde) for 10 minutes. After washing the cultures for three 
times with PBS, they were incubated with hemotoxylin for 4 minutes for staining. 
The plates were washed in distilled water, dried, and photographed to count the 
colonies using software ‘ImageJ’ (National Institutes of Health, Bethesda, MS, 
USA). Clusters of ≥ 50 cells were counted and the cloning efficiency (CE) was 
determined from the formula: cloning efficiency (%) = (number of 
colonies/number of cells seeded) × 100. 
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2.6 Endometrial stromal cell differentiation 
 
2.6.1 Materials: 
 
Antibiotic-antimycotic solution (1%) - Invitrogen, Paisley, UK 
Collagenase (0.5mg/ml) - Sigma-Aldrich, Gillingham, UK 
Deoxyribonuclease type I (0.1mg/ml) - Roche, Burgess Hill, UK  
Dextran-coated charcoal-treated fetal bovine serum (DCC-FBS) (10%) 
Distilled water 
DMEM/F-12 medium - Invitrogen, Paisley, UK 
Estradiol - Sigma-Aldrich, Gillingham, UK 
Insulin - Sigma-Aldrich, Gillingham, UK 
L-glutamine - Invitrogen, Paisley, UK 
gDNA Wipeout Buffer, 7x – QIAGEN, Manchester, UK 
RNA Stat-60 – AMS Biotechnology, Abingdon, UK 
NanoDrop spectrometer - Thermo Scientific, Wilmington, USA.  
Reverse transcriptase enzyme - QIAGEN, Manchester, UK 
RT buffer 5x - QIAGEN, Manchester, UK 
RT primer mix - QIAGEN, Manchester, UK 
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SYBR® Green PCR master mix – Applied Biosystems, Paisley, UK 
7500 Real-time PCR system - Applied Biosystems, Paisley, UK  
Optical 96-well reaction plate - Applied Biosystems, Paisley, UK 
Optical adhesive film – Alpha laboratories, Hampshire, UK 
 
2.6.2 Primary cell culture of human endometrial stromal cells: 
 
The endometrial tissue was collected on a petri-dish, washed in DMEM/F-12 
medium and the fluid around the tissue is removed completely. The endometrial 
tissue was finely minced using a sterile blade for 5 minutes and enzymatically 
digested with 100µl collagenase (0.5mg/ml) and 100µl deoxyribonuclease type I 
(0.1mg/ml) in 10 ml of the medium (DMEM/F-12 without DCC, L-glutamine and 
antibiotics) for 1 hour at 37oC. 10 ml of the maintenance medium, a mixture of 
DMEM/F12 containing 10% dextran-coated charcoal-treated fetal bovine serum 
(DCC-FBS), antibiotic and antimycotic solution, and 1% L-glutamine was added 
to deactivate collagenase and the cells were separated by centrifugation at 
1200 rpm for 5 minutes. The cell pellet was resuspended in 10% maintenance 
medium and the separated endometrial stromal cells (ESCs) were passaged in 
T75 flasks (13 ml of 10% maintenance medium). The proliferating ESCs were 
cultured in maintenance medium, which was changed every two days, until 
confluence.  
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2.6.3 Decidualisation of endometrial stromal cells in vitro: 
 
The confluent cells were passaged by trypsinisation into 6-well plates and 
further cultured in maintenance medium until confluence. When the cells 
reached 70-80% confluence, 2% maintenance medium (DMEM/F-12 with 2% 
DCC-FBS) was used to synchronise cells.  Confluent monolayer were treated 
for decidualisation in phenol red-free DMEM/F12 containing 2% DCC-FBS, with 
8-bromo-cAMP (0.5 mM) and MPA (10 -6 M) for 0, 4 and 8 days. This medium 
was changed every 48 hours. Supernatants were collected and frozen cells 
harvested for mRNA analysis.  
 
2.6.4 Total RNA extraction: 
 
200µL of RNA Stat-60 was added to each well. Cell lysates were scraped using 
scrapers and were transferred to pre-chilled RNase-free eppendorfs. 80µL of 
ice-cold chloroform was added to each eppendorf (1/5th of the Stat-60 used) 
and the contents were vigorously shaken. The samples were centrifuged in a 
cold room (40 C) at a maximum speed of 16000rpm for 30 minutes. The clear 
top layer was transferred into a second pre-chilled eppendorf and 200µL of ice-
cold iso-propranolol was added (1/2 of the original Stat-60 volume). The 
contents were mixed by vortex and stored at -800 C for at least 30 minutes. The 
contents were centrifuged in a cold room (40 C) at maximum speed of 
16000rpm for 30 minutes. The supernatant was carefully discarded and 1 ml of 
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70% ice-cold Ethanol (made up in nuclease free water) was added to the pellet. 
Following centrifugation in a cold room at a maximum speed of 16000rpm for 30 
minutes, the supernatant was discarded and the pellet was allowed to air dry (2 
minutes). 20µL of RNase-free DEPC water was added to dissolve the pellet and 
the RNA concentration was measured using NanoDrop spectrometer (Thermo 
Scientific, Wilmington, USA).  
 
2.6.5 Reverse transcription and synthesis of complementary DNA 
(cDNA): 
 
The template RNA mean concentration extracted from cell cultures (as 
described above) was calculated by NanoDrop spectrometer. Genomic DNA 
(gDNA) elimination reaction was done (Table) as gDNA contamination can lead 
to false positive results. The components were incubated for 2 minutes at 42°C, 
and then placed immediately on ice. 
 
Component Volume/reaction 
 
gDNA Wipeout Buffer, 7x 
 
2 µl 
Template RNA up to 1 μg* Variable 
 
 
RNase-free water Variable 
 
Total reaction volume 14 µl 
 
 
Table 5.1: Components of gDNA elimination reaction. 
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The reverse transcription (RT) master-mix (MM) is prepared as in table 5.2. The 
components were mixed and then kept on ice. The reverse-transcription master 
mix contains all components required for first-strand cDNA synthesis except 
template RNA. 
 
Component Volume/reaction 
Reverse transcriptase enzyme 1 µl 
RT buffer 5x 4 µl 
RT primer mix 1 µl 
Total reaction volume 6 µl 
Table 5.2: Reverse transcription master-mix (RT MM) components. 
 
Three templates were prepared for isolation of cDNA from the template RNA 
out of which two were controls (i) RT+ (ii) RT- and (iii) Control buffer (CB) or No 
RT control (Tables 5.3, 5.4 and 5.5).  
Component Volume/reaction 
 
Template RNA - entire genomic DNA 
elimination reaction (Table 1) 
 
14 µl 
Reverse transcription master mix 
(Table 2) 
 
6 µl 
Total reaction volume  20 µl 
 
Table 5.3: Reverse transcription reaction components for RT+ template 
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Component Volume/reaction 
 
gDNA elimination reaction without 
template RNA 
 
14 µl 
Reverse transcription master mix 
(Table 2) 
 
6 µl 
Total reaction volume 20 µl 
Table 5.4: Reverse transcription reaction components for RT- template 
 
Component Volume/reaction 
 
Template RNA - entire genomic DNA 
elimination reaction (Table 1) 
 
14 µl 
Reverse transcription master mix 
without RT enzyme, but replaced with 
water 
 
6 µl 
Total reaction volume 20 µl 
 
Table 5.5: Reverse transcription reaction components for CB template (No RT control) 
 
The above reactions were incubated for 30 minutes at 42°C to obtain cDNA, 
and then at 95°C for 3 minutes to inactivate RT enzyme. The reactions were 
placed on ice for real-time polymerase chain reaction (PCR). 
 
2.6.6 Real-time reverse transcription-polymerase chain reaction 
(real-time RT-PCR): 
 
The PCR primer-master mix (PCR primer-MM) was prepared with the ratio of 
components as described in the table 5.6. 
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 Component Volume/reaction 
 
Water 
 
7.8 µl 
SYBR® Green PCR master mix 
 
10 µl 
Primer Mix (Sum of each primer: 
forward + reverse) 
1.2 µl 
 
Total volume 19 µl 
 
Table 5.6: PCR primer-MM components for real time RT-PCR 
 
Specific primer pairs were designed using Primer3 software 
(http://frodo.wi.mit.edu) 
L19 sense: 5’-GCG GAA GGG TAC AGC CAA T-3’  
L19-R antisense: 5’-GCA GCC GGC GCA AA-3’ 
Prolactin (PRL) sense: 5’-AAG CTG TAG AGA TTG AGG AGC AAA C-3’ 
PRL antisense: 5’-TCA GGA TGA ACC TGG CTG ACT A-3’ 
IGFBP1 sense: 5’-CGA AGG CTC TCC ATG TCA CCA-3’  
IGFBP1 antisense, 5’-TGT CTC CTG TGC CTT GGC TAA AC-3’ 
 
In an optical 96-well reaction plate, 19 µl of the above mix was added to each 
well by reverse pipetting and 1 µl of the cDNA (RT+) or blank (RT- or CB or 
Water (No-template control – NTC)) was added into the relevant wells 
according to the template. An optical adhesive film was used to seal the optical 
96-well reaction plate and centrifuged at 3000 rpm for 3 minutes. mRNA gene 
expression was measured on the PCR system. RNA input variances were 
normalized against the levels of the L19 housekeeping gene, which encodes a 
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ribosomal protein, using the 2(-Delta Delta C(T)) method (Livak and Schmittgen, 
2001). All measurements were performed in duplicate. 
 
2.7 Differentiation of endometrial stromal cells in the 
presence of supernatant from adipose tissue explants  
 
The abdominal adipose tissue from the omentum was collected at caesarean 
section from normal weight women and obese women. The cleaned adipose 
tissue was dissected into small pieces and incubated in CMRL-1066 nutrient 
media (Sigma-Aldrich, Gillingham, UK) for 48 hours. The supernatant was 
collected and snap frozen (Obtained from Division of Metabolic and Vascular 
Health, Warwick Medical School, The University of Warwick) 
 
Four sets of primary cell cultures of hESCs were established from endometrial 
biopsies and a confluent monolayer were treated with c-AMP and MPA for 
differentiation as described previously. The first group of cells (Control) were 
allowed to differentiate under normal conditions for 8 days. Three other groups 
of differentiating ESCs were treated with the culture media (CM group: CMRL 
1066 nutrient media) (n=2), supernatant from adipose tissue explants of normal 
weight women (Normal) (n=3) and supernatant from the adipose tissue explants 
of obese woman (Obese) (n=3). mRNA gene expression for decidualisation 
markers (PRL and IGFBP1) were measured on day 8 as described previously 
and the relative expression of decidualisation markers from the CM, normal and 
obese groups were charted against the control group. 
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2.8 Statistical analysis: 
 
Data was checked for normal distribution using histograms and the 
Kolmogorov-Smironov normality test with Lilliefors significance correction or 
Shapiro-Wilk normality test, as appropriate. Data are in mean ± SD, mean ± 
SEM and median ± IQR as required. Pearson’s correlation or Spearman’s 
correlation was used as appropriate for calculation of associations between 
variables. Data were analysed using ordinary one way ANOVA (post hoc 
analysis: Tukey HSD test) or Independent samples T test or Chi-Squared test or 
independent samples Kruskall-Wallis nonparametric test (± pair-wise 
comparison) or independent samples Mann-Whitney U nonparametric as 
appropriate to compare between the BMI groups.  
 
Kaplan-Meier curves were constructed estimating the cumulative probability of a 
spontaneous pregnancy over time. The log-rank (Montel-Cox) test was used to 
test differences between the Kaplan-Meier curves for statistical significance. 
 
All statistical analyses were performed using SPSS version 21.0 (SPSS, Inc., 
Chicago, USA). p < 0.05 was considered significant. 
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CHAPTER 3: 
HIGH BODY MASS INDEX AND FIRST TRIMESTER 
PREGNANCY LOSS PATTERN 
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3.1 Introduction 
 
The commonest adverse outcome associated with pregnancy is miscarriage. An 
estimated 30% of the embryos are lost prior to implantation, a further 30% after 
implantation but before next menstruation and 10% miscarry clinically after a 
missed period (reviewed in Macklon et al., 2002) (Figure 3.1). Chromosomal 
aberrations appear to be common in the pre-implantation embryos which 
predispose to an increased risk of pregnancy losses. Out of the 23 good quality 
embryos examined by Vanneste et al (2009), only two were found to have 
normal karyotype in all blastomeres with nearly half of the embryos had no 
normal cells and the remaining embryos were mosaic for structural 
chromosomal imbalances. A further study that looked at more than 6000 
embryos, many suitable for embryo transfer, suggested that only 44% of the 
embryos with best morphology and development were euploid in women under 
the age 35 and merely 21% were chromosomally normal in women aged 41 or 
more (Munné et al., 2007). However, the prevalence of abnormal karyotype of a 
pregnancy following a single sporadic miscarriage is 45% (95% CI: 38-52), 
which is not significantly different to that for a subsequent miscarriage following 
RM (39%, 95% CI: 29-50) (van den Berg et al., 2012).  
 
Studies have reported that early stages of embryo development are susceptible 
to genetic disorders. However, the outstanding feature of early pregnancy is 
that of a ‘natural embryo selection’ – most of the aneuploid pregnancies (90%) 
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miscarry whereas 93% of karyotypically normal pregnancies continue 
(McFadden, 1989).  
                
Figure 3.1: The embryo wastage iceberg in fertile and superfertile women.  The embryo 
wastage icebergs give an overview of the outcome of conceptions in a normal fertile 
population and a speciﬁc subset of a superfertile population, representing 3% of all 
couples. The ‘sea-level’ in the ﬁgure distinguishes the pregnancies lost prior to the time 
of the missed menstrual period and clinically recognized pregnancy losses. (with 
permission from Oxford Journals: Teklenburg et al., (2010) The molecular basis of 
recurrent pregnancy loss: impaired natural embryo selection. Mol Hum Reprod. 
16(12):886-95.) 
 
 
Epidemiological studies have indicated a robust association between increased 
maternal age and both spontaneous miscarriage and RM (Quenby and 
Farquharson, 1993; Nybo Anderson et al., 2000) indicating that embryo 
abnormality to be an important aetiological factor in miscarriage. While most of 
the embryo chromosomal abnormalities are as a result of oocyte aberrations 
associated with advanced maternal age (Robinson  et al., 2001), there is also 
an association between abnormal sperm chromosome from the male partners 
of women experiencing RM (Egozcue et al., 2003) signifying the role of paternal 
factors in causing embryo abnormalities.  
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There is a lack of good quality evidence to suggest the effects of high BMI on 
early pregnancy outcome, but the evidence from observational studies, mostly 
retrospective, suggested that high BMI may be a risk factor for an increased risk 
of first trimester miscarriage and recurrent miscarriage (RM) in women who 
conceived spontaneously (Boots and Stephenson, 2011). Similarly, the impact 
of obesity on miscarriage rate after assisted reproduction technology (ART) 
remains less clear and inconsistent. However, a recent systematic review and 
meta-analysis of the existing literature, mainly retrospective studies, suggested 
that women with a high BMI (≥ 25.0) have an associated increased miscarriage 
rate after ART treatment (Rittenberg et al., 2011a). A further study that 
examined the effect of BMI on miscarriage rate following ART using single 
blastocyst transfer demonstrated that women with a BMI between 25 and 35 are 
more than twice likely to have a clinical miscarriage compared to normal weight 
women, both in fresh and cryo-thawed cycles (Rittenberg et al., 2011b). 
 
The pattern of early pregnancy loss in first trimester (EPL) provides an insight 
into the association with chromosomal abnormality of a miscarriage (Morikawa 
et al., 2004). With the availability of sensitive urine and serum b-hCG 
measurements in combination with high resolution trans-vaginal ultrasound, it is 
now possible to categorise early pregnancy losses into embryo loss (EL) – 
miscarriage of a pregnancy before a fetal heart is identified including empty 
gestational sac losses and fetal loss (FL) – miscarriage of a pregnancy once the 
fetal heart is seen on an ultrasound scan (Bricker and Farquharson, 2002), 
biochemical pregnancy loss - where the pregnancy was diagnosed by either 
serum or urine b-hCG without an ultrasound evaluation and the serial results 
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suggesting a pregnancy loss, pregnancy of unknown location - pregnancy loss 
not visualized on ultrasound with resolution of serum hCG and ectopic 
pregnancy – pregnancy outside the uterine cavity. The EPL pattern is not only 
essential for management, prognosis and follow-up of these women, particularly 
for women with recurrent miscarriage, but also provides an insight into an 
association with chromosomal abnormality of the implanting embryo. 
 
My literature review in chapter 1, suggested that high BMI may be responsible 
for increased risk of spontaneous early pregnancy losses and a possible 
adverse effect of obesity on the peri-implantation endometrium. 
 
The objectives of this study were [a] to describe the pregnancy loss pattern and 
its correlation to BMI in women who attended a tertiary implantation clinic with 
various reproductive failures and [b] to analyse whether the pregnancy loss 
pattern is significantly different between normal, overweight and obese women.  
          
3.2 Materials and Methods 
 
See chapter 2 
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3.3 Results: 
 
3.3.1 Demographic details: 
 
      
        
 
All subjects 
(313) 
 
Normal 
(n=164) 
 
Overweight 
(n=97) 
 
Obese  
(n=52) 
 
p 
 
Mean (± SD) Age 
 
36.8 (4.7) 
 
36.8(4.6) 
 
37.0 (4.8) 
 
36.3 (5.0) 
 
0.69# 
 
No. of EPL 
 
969 
 
432 
 
326 
 
211 
 
- 
 
Median (IQR) EPL 
 
3.0 (0 – 5.0) 
 
3.0 (0 – 4.0) 
 
3.0 (1.0 – 5.0) 
 
3.0 (2.0 – 6.7) 
 
< 0.05## 
 
No. of BPL 
 
158 
 
84 
 
48 
 
26 
 
- 
 
Median (IQR) BPL 
 
0 (0 - 0) 
 
0 (0 – 0) 
 
0 (0 – 0) 
 
0 (0 – 0) 
 
0.81## 
 
No. of EGSL 
 
525 
 
219 
 
172 
 
134 
 
- 
 
Median (IQR) 
EGSL 
 
0 (0 – 3.0) 
 
0 (0 – 2.75) 
 
0 (0 – 3.0) 
 
1.0 (0 – 5.0) 
 
< 0.05## 
 
No. of FL 
 
239 
 
98 
 
94 
 
47 
 
- 
 
Median (IQR) FL 
 
0 (0 – 1.0) 
 
0 (0 – 1.0) 
 
0 (0 – 1.0) 
 
0 (0 – 1.75) 
 
0.31## 
 
Table 3.1: Maternal age and EPL patterns for all 313 subjects with reproductive failures 
included in the study. EPL: early pregnancy losses in the first trimester; BPL: 
biochemical pregnancy losses; EGSL: empty gestational sac losses; FL: fetal losses; 
SD: Standard deviation; IQR: inter-quartile range. p < 0.05 significant. # One way 
ANOVA, ##: Independent samples Kruskall-Wallis test. 
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A total of 313 women attended the clinic during the study period. The 
Kolmogorov-Smironov normality test with Lilliefors significance correction 
suggested that the data for age were normally distributed whereas the data for 
EPL, BPL, EGSL and FL were not normally distributed. The women were 
classified into three groups according to their BMI: normal (n=164), overweight 
(n=97) and obese (n=52). The demographic details and the clinical information 
for each of these groups are in Table 3.1. Out of the 969 first trimester 
miscarriages identified in these women, 158 (16.3%) were biochemical, 525 
(54.18%) empty gestational sac losses and 239 (24.66%) were fetal losses. 
There was no significant difference in the mean (± SD) age in years for these 
women in different weight groups (p=.69). 
 
3.3.2 Correlation of BMI and reproductive history: 
 
Relationship between BMI and EPL, EGSL and FL indicated a significantly 
positive correlation of EPL (Spearman’s correlation coefficient, rho .178, 
p=.002), EGSL (Spearman’s correlation coefficient, rho .118, p=.037) and FL 
(Spearman’s correlation coefficient, rho .130, p=.022) with BMI, whereas BPL 
was not significantly correlated with BMI (Spearman’s correlation coefficient, rho 
-.027, p=.633) (Figure 3.2). 
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Figure 3.2: Relationship between BMI and EPL, EGSL and FL indicated a significantly 
positive correlation of EPL (Spearman’s correlation coefficient, rho .178, p=.002), 
EGSL (Spearman’s correlation coefficient, rho .118, p=.037) and FL (Spearman’s 
correlation coefficient, rho .130, p=.022) with BMI, whereas BPL was not significantly 
correlated with BMI (Spearman’s correlation coefficient, rho -.027, p=.633). EPL: early 
pregnancy losses in the first trimester; EGSL: empty gestational sac losses; FL: fetal 
losses; BPL: biochemical pregnancy losses. 
r = .17* 
p =.002 
n = 313 
r = .12* 
p =.03 
n = 313 
r = .13* 
p =.02 
n = 313 
r = -.03 
p =.63 
n = 313 
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3.3.4 Pregnancy loss pattern in BMI groups: 
 
The Kruskal-Wallis test indicated a significant difference existed in the 
distribution of first trimester miscarriages among the three groups (T=10.007, 
df=2, p=.007) (Figure 3.3). A pair wise comparison was performed as a post-
hoc follow-up which suggested a significant difference between the obese and 
normal weight women (p=.011), but there was no statistically significant 
difference between normal-overweight (p=.125) and overweight-obese (p=.706) 
groups.  
 
Out of the 525 empty gestation sac pregnancy losses, 219 were in the normal 
weight women, 172 in overweight and 134 in obese women. The Kruskal-Wallis 
test indicated a significant difference in the distribution of EGSL existed among 
the three groups (T=7.658, df=2, p=.022) (Figure 3.4). A pair wise comparison 
suggested a significant difference between the obese and normal weight 
women (p=.018), but there was no statistically significant difference between 
the other groups (normal-overweight: p=.846; overweight-obese: p=.241) 
 
There was no statistically significant difference in the number of fetal losses 
(T=2.331, df=2, p=.312) and biochemical pregnancy miscarriages (T=0.406, 
df=2, p=.816) between three groups. 
  
109 
 
 
   
 
Figure 2.3: The box and whisker plot showing the number of first trimester miscarriages 
in women with normal, overweight and obese women. The results of the Kruskal-Wallis 
test and pairwise comparisons for women with different weight groups are shown. A 
significant difference in the distribution of first trimester miscarriage was observed 
between obese and normal weight women. 
  
p < 0.05 
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Figure 3.4: The box and whisker plot showing the number of empty gestation sac 
miscarriages in women with normal, overweight and obese women. The results of the 
Kruskal-Wallis test and pairwise comparisons for women with different weight groups 
are shown. A significant difference in the distribution of empty gestational sac losses 
was observed between obese and normal weight women. 
  
p < 0.05 
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3.4 Discussion 
 
My study findings from a relatively large cohort of women, who attended a 
tertiary referral implantation clinic, support the evidence that obesity increases 
the risk of first trimester pregnancy loss. There is also a significant positive 
correlation between first trimester pregnancy losses and BMI. 
 
From this study, I present a novel data of increased loss of empty gestational 
sac pregnancies or anembryonic miscarriages in obese women when compared 
to normal weight women. A significant positive correlation between the BMI and 
EGSL was also demonstrated.   
 
Morikawa et al., (2004) examined miscarriage type and karyotype in RM women 
and found that embryo losses (included EGSL and embryonic miscarriages with 
embryo less than 3mm) are more likely to be karyotypically normal embryos 
whereas slightly advanced pregnancy losses (included FL with embryo more 
than 3mm and fetal miscarriages) are more likely to be pregnancies with 
abnormal karyotype. So the findings of our study may indicate that obese 
women have an increased risk of miscarriage of pregnancies which are less 
likely to have karyotypic abnormality i.e. due to oocyte abnormalities. This is in 
keeping with the findings of a study by Landres et al., (2010) which suggested 
that women with a BMI ≥ 25 are associated with an increased risk of 
miscarriage of embryos with a normal genetic component. A recent study by 
Boots et al., (2014) also proposed that obese women with RM have an 
increased risk of euploid miscarriage.   
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Endometrial dysfunction has been proposed to increase the risk of reproductive 
failures in obesity (Landres et al., 2010; Bellver et al., 2013) and our study 
findings appear to support this concept. It is likely that an impaired peri-
implantation endometrial development associated with obesity predisposes to 
early implantation problems and therefore increases the risk of miscarriage of 
pregnancies with normal karyotype. Bellver et al., (2013) using first cycle ovum 
donation IVF/ICSI cycles with eggs obtained from normal weight donors, 
suggested that implantation, clinical pregnancy and live birth rates in recipients 
were significantly reduced with an increase in BMI.   
 
The other possible explanation for an increased anembryonic miscarriage in 
obese women may be due to nutritional deficiencies associated with obesity. 
The EGSL can be considered to be a structural abnormality of pregnancy as 
there is no evidence of a fetus at the time of a miscarriage. The structural 
abnormalities are more common in obese women which are thought to be due 
to poor dietary habits of obese women who are often deficient in vitamins. 
Hence CMACE/RCOG joint guidelines (13) recommend the use of high dose 
folate and vitamin D supplements for all obese pregnant women. 
 
Though in my study, the FL showed significantly positive correlation with BMI, 
there was no significant difference in the number FL between normal weight, 
overweight and obese subjects. A previous study which prospectively 
investigated 1200 ultrasound confirmed ongoing singleton intrauterine 
pregnancy at a mean gestational age of 9+ weeks did not find any significant 
difference in miscarriage rate in normal, overweight and obese women (Turner 
113 
 
et al., 2010). However, a recent study has suggested that in a first pregnancy, 
moderate and severe obesity increase the risk of fetal miscarriage following an 
ultrasound confirmation of fetal cardiac activity in the first trimester (O’Dwyer et 
al., 2012). 
 
In my study, there was no significant difference in the number of biochemical 
pregnancy losses between obese and non-obese subjects. These are the 
spontaneously resolved pregnancies of unknown location and therefore could 
be anywhere in the upper reproductive tract (in fallopian tube, pelvis and on 
ovaries) or cervical canal and therefore not necessarily of endometrial aetiology. 
 
The strength of my study is that it includes a relatively large sample size. My 
work has demonstrated an important association between early pregnancy loss 
patterns and BMI. I also report for the first time that superfertility is more 
prevalent in obese women presenting with recurrent miscarriage. We used the 
WHO classification of BMI to categorise women into different weight groups.  
 
However, our study has several limitations and the main one relate to the 
retrospective data collection. The women at presentation to the clinic may not 
accurately remember the exact nature of first trimester pregnancy loss. The BMI 
at the time of an adverse pregnancy outcome may be different to BMI at 
presentation in the clinic which could have led to cross-over of women between 
the groups. Maternal age plays a vital role in predisposing women to a 
miscarriage. There was no difference in the age of women across the BMI 
114 
 
groups, but the age at presentation may not be a true reflection of the age at 
adverse outcome.  
 
3.5 Conclusions: 
 
By analysing a large number of women for their first trimester pregnancy loss 
pattern, my study supports the evidence that obesity may increase the risk of 
spontaneous first trimester pregnancy losses. In addition, the findings of an 
increased anembryonic miscarriage in obese women suggests of a possible 
increased loss of euploid embryos as a result of an endometrial dysfunction in 
the peri-implantation period. The findings of this study may assist in designing 
large, well-designed, prospective studies which are essential to establish the 
effects of BMI on first trimester pregnancy loss patterns. 
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CHAPTER 4: 
THE EFFECT OF OBESITY ON TIME TO PREGNANCY 
INTERVAL AND EARLY PREGNANCY LOSS PATTERN IN 
WOMEN WITH RECURRENT MISCARRIAGE 
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4.1 Introduction 
 
Loss of three or more consecutive pregnancies before 24 weeks of gestation is 
the most acceptable definition for recurrent miscarriage (RM) (Stirrat 1990) in 
Europe, but has recently been defined by the American Society for 
Reproductive Medicine as two or more failed pregnancies (ASRM, 2008). 
 
The time taken to achieve pregnancy (TTP) expressed as monthly fecundity 
rates (MFR), i.e. the probability of achieving a pregnancy within one menstrual 
cycle (Evers, 2002) can be used to measure the fertility rates. The average 
MFR for couples is relatively low at 20% (Leridon and Spira, 1984) and high 
prevalence of aneuploid human embryos may be responsible for this relative 
reproductive inefficiency in humans. Based on the MFR, it is predicted from a 
simple hypothetical model that 74, 93 and 100% of normal fertile couples will 
conceive within 6, 12 and 24 months, respectively (Evers, 2002). One in six 
couples in developed countries are affected with subfertility and infertility and 
these couples have a reproductive inefficacy with MFR of 1-5% and 0%, 
respectively (Evers, 2002). Whereas, 3% of the couple have superfertility with a 
MFR of 60% or more and can achieve 94% and 100% of pregnancies within 3 
and 6 months, respectively (Evers, 2002). It is also predicted that the proportion 
of women achieving 3 or more consecutive pregnancies within 1, 3 and 6 
months to be 0.8%, 8% and 41% respectively (Salker et al., 2010). Superfertility 
in RM women is more than the average expected for general population and 
these women with RM report a very short TTP (Salker et al., 2010). This 
supports the concept that an increase MFR in RM women is likely to be a result 
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of a prolonged implantation window secondary to an impaired endometrial 
decidualisation, which allows even the developmentally compromised embryos 
to implant which subsequently miscarry. 
 
We hypothesised that obese women with recurrent miscarriage have a 
significantly shorter time to pregnancy and an increased first trimester 
pregnancy losses with no difference in the pregnancy loss pattern when 
compared to normal weight women with recurrent miscarriage. 
4.2 Subjects and Methods 
 
See chapter 2 
 
 4.3 Results 
 
4.3.1 Demographic details: 
 
A total of 177 women who attended the clinic during the study period were 
identified to have had a history of RM. The demographic details and the clinical 
information for each of these groups are in Table 4.1. The data for age was 
normally distributed, whereas the data for EPL, EGSL, FL and BPL were not 
normally distributed. 
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All 
subjects  
(n=177) 
 
Normal 
(n=84) 
 
Overweight 
(n=57) 
 
Obese  
(n=36) 
 
 
p 
 
Mean (± SD) Age 
 
36.9 (4.5) 
 
36.5 (4.3) 
 
37.2 (4.7) 
 
37.3 (4.3) 
 
0.60# 
 
No. of EPL 
 
879 
 
383 
 
294 
 
202 
 
- 
 
Median (IQR) EPL 
 
4 (3 – 6) 
 
4 (3 – 5) 
 
4 (3.5 – 6) 
 
5 (3 – 7) 
 
<0.05## 
 
No. of BPL 
 
129 
 
66 
 
42 
 
21 
 
- 
 
Median (IQR) BPL 
 
0 (0 - 0) 
 
0 (0 – 1) 
 
0 (0 – 1) 
 
0 (0 – 0) 
 
0.39## 
 
No. of EGSL 
 
495 
 
204 
 
160 
 
130 
 
- 
 
Median (IQR) 
EGSL 
 
3 (0 – 4) 
 
2 (0 – 4) 
 
2 (0 – 4) 
 
3 (1 – 6) 
 
0.18## 
 
No. of FL 
 
211 
 
84 
 
 
83 
 
44 
 
- 
 
Median (IQR) FL 
 
0 (0 – 2) 
 
0 (0 – 2) 
 
0 (0 – 2) 
 
0 (0 – 2) 
 
0.79## 
 
Table 4.1: Maternal age and EPL patterns for all 177 subjects with recurrent 
miscarriage. EPL: early pregnancy losses in the first trimester; BPL: biochemical 
pregnancy losses; EGSL: empty gestational sac losses; FL: fetal losses; SD: Standard 
deviation; IQR: inter-quartile range. p < 0.05 significant. # One way ANOVA, ##: 
Independent samples Kruskall-Wallis test. 
 
4.3.2 Correlation of BMI and pregnancy loss pattern in women with 
recurrent miscarriage 
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Relationship between BMI and EPL indicated a significantly positive correlation 
of EPL (Spearman’s correlation coefficient, rho .160, p=.033) with BMI, whereas 
EGSL (Spearman’s correlation coefficient, rho .077, p=.311) and FL 
(Spearman’s correlation coefficient, rho .082, p=.275) BPL (Spearman’s 
correlation coefficient, rho -.068, p=.369) were not significantly correlated with 
BMI (Figure 4.1). 
        
        
Figure 4.1: Relationship between BMI and EPL indicated a significantly positive 
correlation of EPL (Spearman’s correlation coefficient, rho .160, p=.033) with BMI, 
whereas EGSL (Spearman’s correlation coefficient, rho .077, p=.311) and FL 
(Spearman’s correlation coefficient, rho .082, p=.275) BPL (Spearman’s correlation 
coefficient, rho -.068, p=.369) were not significantly correlated with BMI. EPL: early 
pregnancy losses in the first trimester; EGSL: empty gestational sac losses; FL: fetal 
losses; BPL: biochemical pregnancy losses. 
 
r = .077 
p =.311 
n = 177 
r = -.068 
p =.369 
n = 177 
r = .082 
p =.275 
n = 177 
r = .160* 
p =.033  
n = 177 
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4.3.3 Pregnancy loss pattern of women with recurrent miscarriage 
in different body mass index groups 
 
The Kruskal-Wallis test indicated a significant difference existed in the 
distribution of first trimester miscarriages among the three groups (T=6.047, 
df=2, p=.049) (Figure 4.2). A pair-wise comparison did not identify any 
statistically significant difference between the obese and normal weight women 
(p=.079), normal-overweight (p=.250) and overweight-obese (p=1.00) groups.  
         
         
 
Figure 4.2: The box and whisker plot showing the number of first trimester miscarriages 
in women with normal, overweight and obese women with a history of RMC. The 
results of the Kruskal-Wallis test and pairwise comparisons for women with different 
weight groups are shown.  
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There was no statistically significant difference in the number of empty 
gestational sac losses (T=3.400, df=2, p=.183), fetal losses (T=.471, df=2, 
p=.790) and biochemical pregnancy miscarriages (T=1.884, df=2, p=.390) 
between the three groups (not shown). 
 
4.3.4 Time to pregnancy intervals 
 
The data for RM, BMI and time to pregnancy intervals was available for a total 
of 154 women.  The women were classified according to their BMI into normal 
(n=74), overweight (n=47) and obese (n=33) groups (Table 4.2).  
 
 
Overall, 33% conceived within I month, 55% within first three months and 69% 
within the first six months, significantly quicker than that predicted in a normal 
fertile population (0.8%, 8% and 41% respectively, adapted from Salker et al., 
2010). Obese women had cumulative pregnancy rates of 71.4% and 85.7% by 
3 and 6 months respectively which was higher than the cumulative pregnancy 
rates for normal weight (48.4% and 64%) and overweight (52.6% and 63.1%) 
groups (Table 4.3).  
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BMI (Binned) Total number Number of 
Events 
Censored 
N Percent 
 
Normal 
 
74 
 
74 
 
0 
 
0.0% 
 
Over weight 
47 47 0 0.0% 
 
Obese 
33 33 0 0.0% 
 
Overall 
154 154 0 0.0% 
 
 
Table 4.2: Number of women with recurrent miscarriage and time to pregnancy 
intervals 
 
    
1 Month 
  
  
3 Months 
  
6 Months 
    
Predicted 
  
0.8% 
  
  
 8%  
  
41% 
  
Overall (n=154)  
  
 
33% 
  
 
55% 
  
 
69% 
  
Normal BMI (n=74) 
  
 
32.8% 
  
 
48.4% 
  
 
64% 
  
  
Overweight (n=47)  
  
 
28.9% 
  
 
52.6% 
  
 
63.1% 
  
Obese (n=33) 
  
 
39.2% 
  
 
71.4% 
  
 
85.7% 
 
Table 4.3: Summary of ≥ 3 cumulative pregnancy rates predicted at 1 month, 3 months 
and 6 months for the general population and women included in this study. The women 
were grouped into normal, overweight and obese according to their BMI. 
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Comparison of survival curves using Kaplan–Meier statistics (Mantel-Cox log 
rank test) indicated a significant difference (p < 0.05) in the mean time in 
months to conceive at 3 months for obese women with RM when compared to 
normal and overweight women with RM (Figure 4.3).  
 
                   
  
Figure 4.3: Kaplan-Meier survival curves for TTP intervals for normal, overweight and 
obese women. The overall comparison using log rank (Montel-Cox) indicated a 
statistically significant difference amongst the groups with more obese women with RM 
had a shorter TTP when compared to normal and overweight women.  
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 4.4 Discussion 
 
My study findings, from a relatively large cohort of women with a history of RM, 
support the evidence that increased female BMI has a negative influence on the 
early pregnancy outcome.  
 
In these women who attended our tertiary referral implantation clinic, I found a 
significant positive correlation between the BMI and first trimester pregnancy 
losses (EPL), but no significant correlation between BMI and EGSL, FL and 
BPL. My study also found a statistically significant difference in the first 
trimester miscarriages in different weight groups classified according to their 
BMI, but failed to identify significant difference in the EGSL, FL and BPL.  
 
A previous study that examined miscarriage type and fetal karyotypes in RM 
women found that, embryo losses (EGSL) are more likely to be karyotypically 
normal embryos and FL to be aneuploid embryos (Morikawa et al., 2004). So 
the findings of our study indicate that in women with a history of RM, obesity 
increases the risk of first trimester miscarriages, but it does not affect the type of 
miscarriage and hence likely the karyotype of the conceptus. The BMI has no 
significant effect on the miscarriages of both euploid and aneuploid pregnancies 
in women with RM. This finding is in contrary to the hypothesis by Salker et al., 
(2010) which proposed that RM could primarily reflect poor embryo selection, 
accounting for an increased prevalence of aneuploidic miscarriages and to the 
findings of Sugiura-Ogasawara et al., (2012) which found that aneuploidy was 
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the most common cause of RM and of Boots et al., (2014) which suggested that 
obese women with RM have an increased frequency of euploid miscarriage.  
 
The other findings of my study support the concept of ‘biological superfertility’ 
within a RM population and of a novel finding that superfertility is more 
prevalent amongst obese than in normal weight women with a history of RM. 
 
The overall ≥ 3 cumulative pregnancy rates in our study group was 55% and 
69% by 3 months and 6 months, respectively, which is significantly quicker than 
that predicted for a normal fertile population (8% and 41% respectively). These 
findings are consistent with the findings of a study by Salker et al., (2010) who 
demonstrated that women with RM reported a considerably shorter time to 
pregnancy. In their retrospective analysis of TTP from women attending a 
tertiary service level RMC clinic, 41% of the women with history of RMC had a 
time to pregnancy interval of 3 months or less compared to 8% as predicted for 
general population. A recent study by Orlando and Coulam (2014) also 
identified that a 32% of the women with RM in their cohort are superfertile.  
 
From my study population, I report a novel finding of significantly more obese 
women achieved pregnancy within 3 months (71.4%) when compared to normal 
weight (48.4%) and overweight (52.6%) women.  
 
My work has highlighted important connections between BMI, RM and 
superfertility. There is a good body of evidence, from in-vitro studies, to suggest 
that inability of the peri-implantation endometrium to mount an adequate 
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decidual response impairs embryo recognition and selection upon implantation 
(Salker et al., 2010; Salker et al., 2011; Salker et al., 2012; Weimer et al., 
2012), which leads to shorter TTP intervals and predispose to RM (Salker et al., 
2010). This abnormal phenotype results in extended window of implantation 
which reduces the endometrial ability to be ‘selective’ in response to embryo 
quality (Teklenburg et al., 2010a). This concept is consistent with the previously 
reported association of late implantation of the embryos with an increased risk 
of early miscarriage (Wilcox et al., 1999).  
 
My findings suggest that obesogenic environment may have a negative 
influence on the peri-implantation endometrium which results in an increased 
prevalence of ‘biological superfertility’ in obese women when compared to 
normal and overweight women, which in turn predisposes them to RM. This 
impaired endometrial transformation with an extended window of implantation 
allows the embryos, both developmentally competent as well as compromised, 
to implant, but finally results in a clinical EPL as the endometrium fails to 
support the highly orchestrated implantation. The pregnancies that are lost as a 
result of superfertility could either be euploid or aneuploid, which explains the 
finding of no different EGSL and FL between different weight groups. 
 
The strength of my study is that it includes a relatively large sample size. My 
work has demonstrated an important association between early pregnancy loss 
patterns and BMI. I also report for the first time that superfertility is more 
prevalent in obese women presenting with recurrent miscarriage. I used the 
WHO classification of BMI to categorise women into different weight groups. 
127 
 
However, the study has several limitations which relate to data collection. The 
women at presentation to the clinic may not accurately remember the exact 
nature of EPL and the exact time required to achieve each pregnancy. The BMI 
at the time of an adverse pregnancy outcome may be different to BMI at 
presentation to the clinic which could have led to cross-over of women between 
the groups. Maternal age plays a vital role in predisposing women to a 
miscarriage. Conception and successful pregnancy are dependent on many 
variables and maternal age plays a vital role in predisposing women to 
miscarriages. Though there was no significant difference in the age of women 
across the BMI groups, the age at presentation to the clinic may not be a true 
reflection of the age at the time of adverse outcome. 
 
4.5 Conclusions 
 
The findings of my study support the evidence that the metabolic effects of 
obesity may cause reproductive failure by its harmful effects on the 
endometrium, which impairs the fine balance between receptivity and embryo 
selection. Further research to describe the peri-implantation endometrium and 
to study the exact mechanism by which the obesity affects endometrium is 
required. If confirmed, clinical trials with therapeutic targets to improve 
decidualisation and thus reproductive outcome in obese women could hold 
significant clinical potential. 
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CHAPTER 5: 
DOES OBESITY AFFECT UTERINE LEUCOCYTE 
POPULATION? 
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5.1 Introduction: 
 
Obesity represents a state of chronic subclinical inflammation. Hypertrophy of 
the adipocytes leads to hypoperfusion and hypoxia and endoplasmic reticulum 
(ER) stress are some of the mechanisms by which obesity results in increased 
adipose tissue inflammation. (Bluher M. 2009). Increased release of fatty acids, 
hormones, and pro-inflammatory molecules occur in obesity which is due to 
altered adipose tissue metabolic and endocrine function. Reactive peripheral 
leukocytosis and elevated acute phase reactants are found to be associated 
with obesity. (Herishanu et al., 2006) 
 
As discussed in chpater 1, there has been a growing interest in endometrial 
leucocyte population among women with poor reproductive outcome (Quenby et 
al., 1999; Quenby and Farquharson, 2006). Obese pregnant women are found 
to have an increased systemic and placental inflammation and associated 
endocrine and immune functions (Stewart et al., 2007; Challier et al., 2008). 
Defective decidualisation is associated with women with a high uNK cell density 
of more than five percent in the peri-implantation endometrium (Kuroda et al., 
2013). Women with RMC have increased uNK cell density in the peri-
implantation endometrium (Lachapelle et al., 1996; Quenby et al., 1999, 2005, 
2009; Tuckerman et al., 2007). 
 
We hypothesised that the leucocytes density in the peri-implantation 
endometrium, the immune cells which are likely to play a role in reproductive 
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success, is significantly different in obese women when compared to that of 
normal weight women. 
 
5.2 Materials and Methods 
 
As described in chapter 2 
 
5.3 Results 
 
5.3.1 Uterine natural killer cells 
 
.  
 
a 
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Figure 5.1: Immunohistochemical staining of CD56+ cells in the human peri-
implantation endometrium. a) Negative control stained with mouse IgG; b) subject with 
< 5% of the uNK cell density; c) high (>5%) uNK cell density. 400 x Magnification       
           
5.3.1.1 Demographic details: 
 
The endometrial biopsies were obtained from a total of 319 women, but the uNK 
cell density was available for 304 women. The others were not suitable for uNK 
b 
c 
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cell analysis. Tests for normality suggested that age was the only variable that 
was normally distributed, whereas uNK cell density, BMI, number of livebirths, 
first trimester miscarriages, number of biochemical losses, number of fetal 
losses, number of empty gestational sac losses did not pass the normality test. 
These women were categorized into three groups according to their BMI – 
Normal BMI (n=162), Overweight (n=92) and Obese (n=50). The demographic 
details are in Table 5.1).    
 
 
  
Normal 
(n=162) 
  
Overweight 
(n=92) 
  
  
Obese  
(n=50) 
  
p 
 
Age in years – 
Mean (± SD) 
 
  
40.73  
(± 4.67) 
  
41.09 
 (± 4.77) 
  
40.33  
(± 4.86) 
  
  .501# 
  
BMI (Kg/m
2
) - 
Median (IQR) 
  
22  
(21 - 23) 
  
  
26.7 
(25 - 28) 
  
33.0 
(30 - 36) 
  
<.0001***## 
  
Women with 
previous Live Birth 
(%) 
  
 
  
34 (20.98) 
  
 
22 (23.91) 
  
 
11 (22) 
  
 
.864### 
  
Recurrent 
Miscarriage (%) 
  
84 (51.85) 
  
53 (57.60) 
  
34 (68.84) 
  
.125### 
Table 5.1: Summary of clinical details of the study population who were assessed for 
peri-implantation endometrial uterine natural killer cell density. #: One-way ANOVA, ##: 
Kruskall-Wallis non parametric test, ###: Chi square test, *** statistically significant 
difference. 
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5.3.3.2 Correlation of BMI and uNK cell density: 
 
BMI was not significantly correlated with uNK cell density. Spearman’s rank 
correlation coefficient (rho) was -.035 with two-tailed p=.538. (Figure 5.2) 
                       
 
Figure 5.2: Scatter plot of correlation of uNK cell density and BMI (n=304). No 
significant correlation was observed (Spearman's rho = -.035, p=.538) 
 
 
5.3.3.3 uNK cell density in BMI groups: 
 
The median (IQR) uNK cell density in the normal weight group was 5.85 (3.19 – 
9.61) compared to 4.81 (3.20 – 9.53) in the overweight group and 4.97 (3.17 – 
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9.05) in obese group (Figure 5.3). An independent samples Kruskal-Wallis test 
indicated no significant difference in the distribution of uNK cells among the 
three groups (T=.576, df=2, p=.758). 
                   
Figure 5.3: Box and whisker plot showing the uNK cell density in the peri-implantation 
endometrium from women of different BMI groups. No significant difference in the 
distribution of uNK cell density in different weight groups. Kruskal-Wallis nonparametric 
test, p=.758 
 
5.3.3.4 uNK cell density and age 
 
The age and uNK cell density was available from 299 women. The distribution 
of uNK cell density was not normally distributed in different age groups. Age 
was not significantly correlated with uNK cell density. Spearman’s rank 
correlation coefficient (rho) was .041 with two-tailed p=.484. The women were 
grouped according to their age, (i) Age less than 35 years (n=105), (ii) Age 
between 35 - 39.9 years (n=122) and (iii) Age ≥ 40 years (n=72). An 
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independent samples Kruskal-Wallis test indicated no significant difference in 
the distribution of uNK cells among the three groups (T=.923, df=2, p=.630) 
(Figure 5.4). 
                            
 
Figure 5.4: Scatter plot of correlation of uNK cell density and age (n=299). No 
significant correlation was observed (Spearman's rho = .041, p=.484). Box and whisker 
plot showing the uNK cell density in different age groups. 
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5.3.3.5 The effect of BMI on uNK cell density in women with RM 
 
There were 171 women with RMC and they were categorized into three groups 
according to their BMI at presentation – normal (n=84), overweight (53) and 
obese (n=34). There was no significant correlation between the uNK cell density 
in the peri-implantation endometrium and BMI in women with a history of RMC 
(Spearman’s rho, correlation coefficient = .095, p.219) (Figure 5.5).  
 
                     
Figure 5.5: Scatter plot showing correlation of BMI and uNK cell density in women with 
RMC. No significant correlation was observed (Spearman's rho = .095, p=.219) 
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The median (IQR) uNK cell density in the normal weight women with RMC was 
5.18 (3.00 – 8.41) compared to 4.80 (3.20 – 7.99) in overweight women with 
RMC and 5.42 (3.81 – 8.33). An independent samples Kruskal-Wallis test 
indicated no significant difference in the distribution of uNK cells existed among 
the three groups (T=1.826, df=2, p.401) (Figure 5.6). 
 
                    
Figure 5.6: Box and whisker plot showing the uNK cell density in the peri-implantation 
endometrium from RMC women of different BMI groups. No significant difference in the 
distribution of uNK cell density in different weight groups of women with RMC. Kruskal-
Wallis nonparametric test, p=.401) 
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5.3.2 Macrophages 
 
 
 
 
a 
b 
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Figure 5.7: Immunohistochemical staining of CD14+ cells in the human peri-
implantation endometrium. a) Negative control stained with mouse IgG; Sub-epithelial 
region of the endometrium with stromal cells stained in purple with b) low density and 
c) high density macrophages in brown. 400 x Magnification. 
 
5.3.2.1 Demographic details: 
 
The endometrial biopsies were obtained from 20 women (Table 5.2) and they 
were categorized into two groups according to their BMI – Normal BMI (n=10) 
and Obese (n=10). The age and BMI were normally distributed, whereas the 
first trimester miscarriages and macrophage density did not pass the normality 
test. There was no statistically significant difference in the mean (± SD) age in 
years between these two groups. The distribution of first trimester miscarriages 
was significantly higher in obese women compared to normal weight women 
(Table 5.3).  
  
c 
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Age in 
years 
Hospital Number No of first trimester 
miscarriages 
BMI Macrophage 
density (%) 
42 AA1435715 3 23 10.75 
38 AA1451290 4 21 5.92 
41 AA1452040 4 21.5 3.7 
31 AA1492850 2 20 4.73 
36 AA1456186 0 24 0.89 
39 AA1461100 3 18 9.22 
35 AA1475799 0 23.5 4.35 
33 AA1484437 3 22 3.74 
33 AA1493198 3 21 3.86 
37 AA1495478 6 21 5.79 
     
38 AA1437164 4 30 4.03 
31 AA1467510 0 30.8 3.08 
35 AA1454032 9 37.5 5.08 
32 AA1462077 7 41 9.89 
29 AA1406130 8 43 5.28 
27 AA1480451 8 36 9.25 
33 AA1482020 5 31 4.95 
27 AA1488932 6 34 2.79 
41 AA1491000 3 32 4.47 
35 AA1495502 7 35 5.06 
 
Table 5.2: Individual clinical data of women assessed for macrophage density 
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Normal 
(n=10) 
  
Obese  
(n=10) 
  
p 
  
Age in years – 
Mean (± SD)  
  
  
36.85  
(3.61) 
  
33.44 
(4.73) 
  
  .417# 
  
BMI (Kg/m
2
) - Mean 
(± SD) 
  
21.5  
(1.76) 
  
  
35.03 
(4.42) 
  
<.0001***# 
  
Median (± IQR) 
First Trimester 
Miscarriages  
  
 
  
3.0  
(1.5 – 4.0) 
  
 
6.5  
(3.75 – 8.0) 
  
 
< 0.05## 
 
Median (± IQR) 
CD14+ density 
 
4.54 
(3.73 – 6.74) 
 
5.01 
(3.79 – 6.27) 
 
.853## 
 
Table 5.3: Summary of clinical details of the study population for peri-implantation 
endometrial macrophage density, #: Independent samples test, ##: Independent 
samples Mann-Whitney U test. 
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5.3.2.2 Correlation of BMI and macrophage density: 
 
BMI was not significantly correlated with peri-implantation endometrial 
macrophage density. Spearman’s rank correlation coefficient (rho) was .099 
with two-tailed p > 0.05 for macrophage density and BMI (Figure 5.8). 
                  
Figure 5.8: Scatter plot of correlation of macrophage density with BMI (n=20). No 
significant correlation was observed between macrophage and BMI (Spearman's rho = 
.099, p=.677)  
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5.3.2.3 Macrophage density in BMI groups: 
 
The median (IQR) uNK cell density in the normal weight group was 4.54 (3.73 – 
6.74) when compared to 5.01 (3.79 – 6.27). An independent samples Mann-
Whitney test indicated no significant difference in the distribution of 
macrophages existed among the two groups (T=.227, p.853) (Figure 5.9). 
             
Figure 5.9: Independent samples Mann-Whitney U test showing the macrophage 
density in the peri-implantation endometrium from women of different BMI groups. No 
significant difference in the distribution of uNK cell density between normal weight and 
obese women.  
 
 
5.4 Discussion: 
 
In this immunohistochemical study, I have examined a large number of timed 
mid-luteal endometrial samples (n=304) from women with various reproductive 
failures for uNK cell density and have shown that, despite examining a large 
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number  of endometrial biopsies, there is no apparent effect of obesogenic 
environment on uNK cell density. 
 
There is no significant correlation between the BMI and the uNK cell density, 
and the distribution of uNK cell density is not significantly different in women of 
normal, overweight and obese categories. The results also suggest that even in 
women with a history of recurrent miscarriage, obesity does not appear to affect 
the peri-implantation uNK cell density 
 
The findings of this study are consistent with the findings of a previous small 
study (n=28) by Metwally et al., (2007), which investigated the impact of high 
BMI on endometrial morphology in the peri-implantation period in women with 
RMC. In their study, the authors analysed various leucocyte populations by 
immunocytochemistry and showed that uNK cell density (CD56+) was not 
significantly different in high BMI (BMI > 25, n=16) compared with women of 
normal weight (BMI < 25, n=12).  
 
My data from this study also shows that an increase in BMI is not associated 
with any clear effect on the peri-implantation endometrial macrophage density. 
We have shown that maternal obesity is not associated with significantly greater 
CD14+ cells within the peri-implantation endometrium compared with normal 
weight women. In this group of women, there was no correlation between peri-
implantation endometrial CD14+ density and maternal age and BMI.  
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To date, the focus in the literature has been on the immune cell population 
within the placental villi. Contrasting evidence exists regrding the effect of 
obesity on macrophage density in the placental villi with some studies 
suggesting an increase in the resident CD14+ cells by 2-3 fold (Challier et al., 
2007; Farley et al., 2009) in the placenta of obese women when compared to 
non-obese women, whereas the others (Roberts et al., 2012) have found no 
difference in the the number of CD14+ cells within the placental villi of obese 
and normal weight women.   
 
Maternal age is an important contributing factor for an increased risk of adverse 
reproductive outcome in women. Our primary objective was to investigate the 
leucocyte density in the peri-implantation endometrium, but we acknowledge 
that the risk of infertility and miscarriages are more with an increase in the 
maternal age, so we analysed the effect of age on the uterine leucocyte 
population. In this study (n=299), we did not find any significant difference in the 
mean (± SD) age between the groups. We also found no significant correlation 
between maternal age and the uNK cell density (n=299).  
 
These findings are consistent with the findings of previous studies (Clifford et 
al., 1999; Tuckermann et al., 2007) who found no significant correlation 
between maternal age and the number of uNK cells in women with early 
pregnancy RMC. These findings also support the evidence that age related 
fertility issues are unlikely to originate from the endometrium, but are oocyte 
related (Abdalla et al., 1993).  
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One of the greatest strengths of this study is the relatively large sample size in 
assessing the effects of high BMI on uNK cell density. The endometrial samples 
were obtained timed to mid-luteal phase (LH+ 5-10 days) which co-incides with 
an essential endometrial transformation responsible for receptivity and 
selectivity. The WHO classification of BMI was used to categorise women into 
different weight groups. The investigator was blinded to the identity of the slide. 
To our knowledge, this is the first study to address the effects of obesogenic 
environment on the macrophage population, the second most abundant 
leucocytes, in the peri-implantation endometrium. To date, the focus in the 
literature has either been on the macrophage (CD14+) concentration in the peri-
implantation endometrium in RMC versus control group or on the effect of 
obesity on the macrophage (CD14+)  density within the placental villi. We have 
also demonstrated the effects of age on the uterine leucocyte population. 
 
We acknowledge that there are a few limitations which need to be taken into 
account when analysing the results of the study. Firstly, maternal age is an 
important confounding variable in any study on adverse reproductive outcomes. 
As described above, maternal age was unlikely to be of any significance for this 
study.  
 
Secondly, there is a lack of reference technique for assessing the peri-
implantation endometrial leucocyte concentration. Different studies have used 
different methods for the assessment of uNK cell density. Though 
immunohistochemistry is the method used in most of the studies (Quenby et al., 
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1999; Michmata et al., 2002; Tuckerman et al., 2007) as it reveals the location 
of uNK cells, some studies (Lachapelle et al., 1996; Fukui et al., 1999) have 
used flow cytometry for uNK cell testing. Quenby et al., (1999) used frozen 
sections, pressure cooker for antigen retrieval and sub-epithelial region to 
assess the uNK cell density, whereas Tuckerman et al., (2007) used wax 
embedded specimens, microwave for antigen retrieval and random counting of 
uNK cell density including deeper into the section. The uNK cell density can 
either be counted manually or by digital image analysis and the latter produce 
more reproducible results (Drury et al., 2011). We used a similar method as 
described by Tuckerman et al., (2007) for antigen retrieval, but used  the 
method described by Quenby et al., (1999) for manual counting of uNK cell 
density, but from five random fields in the sub-epithelial region at x400 
magnification. Immunohistochemistry has been described for assessing the 
macrophage density in the peri-implantation endometrium (Quenby et al., 1999; 
Quack et al., 2001) and a similar method as described above was used for 
assessing macrophage density in our study. 
 
The number of endometrial biopsies assessed for macrophage density may not 
have sufficient power to reflect the actual effect of BMI on macrophage density. 
Analysing the endometrial samples for markers from morbidly obese women 
(BMI >40) and comparing them with normal weight women with a sufficient 
power calculation may reflect a better endometrial function. 
 
148 
 
5.5 Conclusions: 
 
Despite examining a large number of samples from women with various 
adverse reproductive failure there appears to be no apparent effect of obesity 
on uNK cell density. The study also suggests that high BMI does not stimulate 
macrophage accumulation in the peri-implantation endometrium. My findings 
advocate the concept that obesity, as determined by BMI, is not associated with 
an adverse peri-implantation endometrial immune environment. 
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CHAPTER 6: 
RELATIONSHIP OF PERI-VASCULAR ENDOMETRIAL 
MESENCHYMAL STEM CELLS WITH BMI 
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6.1 Introduction: 
 
As described in Chapter 1, the endometrium is rich in mesenchymal stem-like 
cells (eMSCs) which are essential for cyclic renewal of the endometrium and 
uterine function. They are a resident cell population and are recruited to the 
endometrium in response to hypoxic, proteolytic and inflammatory stimuli 
associated with cyclic menstruation or pregnancy. W5C5 has been identified as 
a novel single marker for purifying eMSCs which self-renew, have high 
clonogenecity and are capable of producing endometrial stroma in vivo  
(Masuda et al., 2012). There have been no studies looking at the effects on BMI 
on eMSCs in the peri-implantation period. 
 
I hypothesised that the abundance and clonogenic efficiency of endometrial 
mesenchymal stem-like cells, which play an important role in endometrial 
regeneration, are impaired in the peri-implantation endometrium of obese 
women when compared to normal weight women. To address this hypothesis, I 
set out to analyse the abundance of W5C5+ cells and their cloning efficiency in 
the peri-implantation endometrium. 
 
6.2 Materials and methods: 
 
Described in chapter 2 
 
151 
 
6.3 Results: 
 
6.3.1 Demographic details: 
 
Endometrial tissue was obtained from a total of 54 women. The Shapiro-Wilk 
test for normality suggested that the data for age, % of W5C5+ cells and % of 
W5C5- cells were normally distributed, whereas the data for BMI, previous 
livebirths, previous first trimester miscarriages, W5C5+ CE and W5C5- CE did 
not pass the normality test. The women were classified into three groups 
according to their BMI: normal (n=22), overweight (n=20) and obese (n=12). 
The demographic details for each of these groups are in Table 6.1. There was 
no significant difference in the mean (± SD) age and the number of live births in 
different weight groups. 
 
                  
 
Figure 6.1: Human endometrial cell clones. Freshly isolated W5C5- (a) and W5C5+ (b) 
cells seeded at 50 cells/cm2 showing individual colonies. 
  
a b 
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Normal 
(n=22) 
  
Overweight 
(n=20) 
  
  
Obese  
(n=12) 
  
p 
 
Age in years - 
Mean (± SD) 
 
  
34.50 (4.48) 
  
36.15 (5.37) 
  
34.67(5.82) 
  
  .547## 
 
BMI (Kg/m2) - 
Median (IQR) 
  
23  
(21.75 - 24) 
  
  
26 
(25 - 28) 
  
32.50 
(30.1 – 37.5) 
  
<.0001***# 
 
No of previous 
Live Births (%) 
 
 
5  
(22.72) 
  
9  
(45) 
  
4  
(33.33) 
  
0.310### 
 
First Trimester 
Miscarriage 
(median ± IQR) 
  
2.0  
(0.0 – 3.25) 
  
3.5  
(1.0 – 5.0) 
  
6.00  
(3.25 – 8.0) 
  
.001#*** 
 
W5C5+ cells (%) 
Mean (± SEM) 
 
 
8.10 (±.92) 
 
6.96 (±.79) 
 
4.94 (±.87) 
 
.078 
 
W5C5- cells (%) 
Mean (± SEM) 
 
 
91.89 (±.92) 
 
93.04 (±.79) 
 
95.05 (±.87) 
 
.078 
 
W5C5+ CE (%) 
Mean (± SEM) 
 
 
3.43 (±.62) 
 
2.21 (±.37) 
 
1.04 (±.32) 
 
.013* 
 
W5C5- CE (%) 
Mean (± SEM) 
 
 
1.19 (±.35) 
 
.52 (±.19) 
 
.19 (±.07) 
 
.047* 
Table 6.1: Summary of demographic, clinical and W5C5 details of the study population. 
# - Independent samples Kruskal-Wallis nonparametric test; ## - One way ANOVA and 
post hoc Tukey HSD test; ### - Chi-square test; *** - p=.001; * - p,.05.  
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Kruskal-Wallis test indicated a significant difference in first trimester 
miscarriages existed among the three groups (T = 13.01, df=2, p=.001) (Figure 
6.2). A pairwise comparison between the groups suggested that the number of 
previous first trimester miscarriages was significantly higher in obese women 
compared to normal weight women (p=.001), but no significant difference 
between the obese-overweight (p=.124) and overweight-normal groups 
(p=.234) were found (see also chapter 2). BMI was significantly positively 
correlated with first trimester miscarriages (Spearman’s correlation coefficient, 
rho .493, p=01), but not with live births (Spearman’s correlation coefficient, rho 
.167, p=.228) (Figure 6.3).     
 
 
 
Figure 6.2: Kruskal-Wallis test indicated a significant difference in the median number 
of first trimester miscarriages amongst different BMI groups. Pairwise comparison of 
distribution of first trimester miscarriages indicated that first trimester losses were 
significantly higher in the obese group when compared to normal weight group 
(p=.001), but there was no significant differences in the obese compared to overweight 
group (p=.124) and overweight women compared with normal weight women (p=.234). 
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Figure 6.3: Relationship between first trimester pregnancy loss and previous live birth 
with Body Mass Index in all subjects. First trimister losses are significantly positively 
correlated with BMI (Spearman correlation coefficient: rho=.493, p=0.01), but live births 
were not significantly correlated with BMI (Spearman correlation coefficient: rho=.167, 
p=.228). 
 
 
6.3.2 The correlation of BMI with % W5C5+ cells, % W5C5- cells, % 
W5C5+ CE and % W5C5- CE:   
 
Overall, an average of 93% of the cells isolated was W5C5- and 7% were 
W5C5+. Of the W5C5+ cells, around 2.45% of the cells were clonogenic, 
whereas only 0.72% of the W5C5- cells were clonogenic. 
 
Relationship between BMI and W5C5+ cell density and W5C5- cell density 
indicated no significant relationship between the percentage of W5C5+ cells 
(Pearson correlation coefficient: r = -.243, p=.760) and W5C5- cells (Pearson 
correlation coefficient: r = .243, p=.760) with BMI (Figure 6.4). 
 
r = .493 
p = .01  
n = 54 
r = .167 
p = .228 
n = 54 
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The relative cloning efficiency of both W5C5+ CE (Pearson correlation 
coefficient: r = -.426, p=.001) and W5C5- CE (Pearson correlation coefficient: r 
= -.376, p=.005) was significantly negatively correlated with the BMI (Figure 6.5)         
            
                     
Figure 6.4: Relationship between % of W5C5+ cells and % of W5C5- cells with BMI. 
No significant correlation was observed between the percentage of W5C5+ cells 
(Pearson correlation coefficient: r = -.243, p=.760) and W5C5- cells (Pearson 
correlation coefficient: r = .243, p=.760) with BMI. 
                  
Figure 6.5: Relationship between % of W5C5+ CE and % of W5C5- CE with BMI. The 
relative cloning efficiency of both W5C5+ CE (Pearson correlation coefficient: r = -.426, 
p=.001) and W5C5- CE (Pearson correlation coefficient: r = -.376, p=.005) was 
significantly negatively correlated with the BMI. 
r = .243 
p = .076 
n = 54 
r = -.243 
p = .076 
n = 54 
r = -.426 
p = .001 
n = 54 
r = .376 
p = .005 
n = 54 
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6.3.3 Effect of BMI on % W5C5+ cells, % W5C5- cells, % W5C5+ CE 
and % W5C5- CE:   
 
One way ANOVA test was carried out to compare the % of W5C5+ and % of 
W5C5- cells among the three groups which indicated no significant differences 
in the relative (%) abundance of W5C5+ cells (p=.078) and % of  W5C5- cells 
(p=.078) between obese, overweight and subjects with normal BMI (Figure 6.6). 
One way ANOVA and post-hoc Tukey’s HSD test indicated that % W5C5+ CE 
was significantly lower in obese subjects compared to subjects with normal BMI 
(p=0.01), but there was no significant difference between overweight-normal 
(p=.18) and obese-overweight groups (p=.320). One way ANOVA suggested a 
significant difference in % W5C5- CE among the groups, but post-hoc Tukey’s 
test showed a trend towards decreased CE in obese women when compared to 
normal weight women, but was not statistically significant (p=.057) (Figure 6.7).    
 
a.      b.     
                                      
Figure 6.6: (a) W5C5+ cells (%) and (b) W5C5 – cells (%) were similar in all BMI 
groups. Data in mean ± SEM. Group comparison by one way ANOVA and post hoc 
Tukey’s HSD test. 
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a.     b.  
Figure 6.7: % W5C5+ CE (a) was significantly less in obese women when compared to 
women with normal BMI. No significant difference in the % W5C5 – CE (b) when 
compared in different BMI groups. Data in mean ± SEM. Group comparison by one 
way ANOVA and post hoc Tukey’s HSD test. 
 
6.3.4 Effect of age on % W5C5+ cells, % W5C5- cells, % W5C5+ CE 
and % W5C5- CE:   
 
We analysed the relationship between maternal age and the % W5C5+, % 
W5C5-, % W5C5+ CE and % W5C5- CE. The women were classified into three 
groups according to their age: less than 35 years (n=22), 35—39.9 years (n=20) 
and more than 40 years (n=12). There was no significant difference in the 
median (± IQR) BMI in different age groups.  
 
Relationship between BMI and W5C5+ cell density and W5C5- cell density 
indicated no significant correlation between W5C5+ cell density (Spearman’s 
** p=.01 
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correlation coefficient, rho -.065, p=.641) and W5C5- cell density (Spearman’s 
correlation coefficient, rho -.022, p=.874) with age. 
 
 
 
 
  
< 35 years 
(n=22) 
 
  
36 – 39 years 
(n=20) 
  
  
40 years 
(n=12) 
 
  
p 
 
BMI (Kg/m
2
) - 
Median (IQR) 
  
25  
(23.0 – 30.1) 
  
  
24 
(23.25 – 26.75) 
  
28.50 
(25.0 – 31.5) 
  
.138# 
 
W5C5+ cells (%) 
Mean (± SEM) 
 
 
7.03 (±.73) 
 
6.84 (±.94) 
 
7.11 (±1.32) 
 
.980## 
 
W5C5- cells (%) 
Mean (± SEM) 
 
 
92.96 (±.73) 
 
93.15 (±.94) 
 
92.88 (±1.32) 
 
.980## 
 
W5C5+ CE (%) 
Mean (± SEM) 
 
 
2.62 (±.44) 
 
2.24 (±.51) 
 
2.47 (±.89) 
 
.871## 
 
W5C5- CE (%) 
Mean (± SEM) 
 
 
.77 (±.26) 
 
.68 (±.28) 
 
.70 (±.39) 
 
.970## 
 
Table 6.2: Summary of demographic, clinical and W5C5 details of the study population 
according to age. # - Independent samples Kruskal-Wallis nonparametric test; ## - One 
way one way ANOVA and post hoc Tukey HSD test. 
 
No significant relationship was observed between the % of W5C5+ cells 
(Pearson correlation coefficient: r = .043, p=.760), % of W5C5- cells (Pearson 
correlation coefficient: r = -.043, p=.760) and the relative cloning efficiency of 
both W5C5+ CE (Pearson correlation coefficient: r = -.147, p=.288) and W5C5- 
CE (Pearson correlation coefficient: r = -.085, p=.543) with age (Figure 6.8). 
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              a.   
                b.     
 
Figure 6.8: a) Relationship between % of W5C5+ cells and % of W5C5- cells with age. 
No significant correlation was observed between the percentage of W5C5+ cells 
(Pearson correlation coefficient: r = .043, p=.760) and W5C5- cells (Pearson correlation 
coefficient: r = -.043, p=.760) with BMI. b) Relationship between % of W5C5+ CE and 
% of W5C5- CE with BMI. No significant correlation was observed between the cloning 
efficiency of both W5C5+ CE (Pearson correlation coefficient: r = -.147, p=.288) and 
W5C5- CE (Pearson correlation coefficient: r = -.085, p=.543) with age. 
 
 
r = -.043 
p = .760 
n = 54 
r = -.147 
p = .288 
n = 54 
r = -.085 
p = .543 
n = 54 
r = -.043 
p = .760 
n = 54 
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One way ANOVA test was carried out to compare the relative cell density and 
CE among the three groups, which indicated no significant differences in the 
relative (%) abundance of W5C5+ cells (p=.980), % of  W5C5- cells (p=.980) % 
W5C5+ CE (p=.871) and % W5C5- CE (p=.970) between the three age groups 
(Figure 6.9). 
 
a.     b.  
c.     d.  
 
Figure 6.9: Group comparison of W5C5+ cell density, W5C5- cell density, W5C5+ cells 
(%), W5C5 – cells (%), W5C5+ CE and W5C5 – CE; a) Results of the Kruskal-Wallis 
test indicated that there was no significant difference in the W5C5+ cell density (T = 
2.690, df=2, p=.261) in all age groups, data in median ± IQR. b)  Results of the 
Kruskal-Wallis test indicated that there was no significant difference in the W5C5- cell 
density were similar in all age groups (T = 5.655, df=2, p=.059), data in median ± IQR. 
One way ANOVA test indicated no significant differences the relative (%) abundance of 
W5C5+ cells (c) (p=.980), (d) % of  W5C5- cells (p=.980), (e) % W5C5+ CE (p=.871) 
and (f) % W5C5- CE (p=.970) between the three age groups, data in mean ± SEM. 
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6.4 Discussion: 
 
In this study I have demonstrated that the cloning efficiency of W5C5+ (eMSCs) 
was significantly reduced in obese subjects when compared to normal weight 
subjects. I also found a significant negative correlation of CE of W5C5+ and 
W5C5- cells with BMI. My study did not find any significant impact of obesity on 
the abundance of W5C5+ cell density and W5C5- cell density in women 
suffering reproductive failures.  
 
My study findings from this group of women has demonstrated again that in 
women with increasing in BMI has a significant positive correlation with a history 
of increased number of first trimester miscarriages (discussed in detail in 
chapter 2).    
 
Clonogenecity (CE) is a remarkable feature of eMSCs which confers incredible 
regenerative capacity to the human endometrium. We demonstrated that the 
cloning efficiency of both W5C5+ and W5C5- cells was significantly negatively 
correlated with the BMI with a significant decreased CE of W5C5+ cells in 
obese women when compared to normal weight women.  
 
These findings from my study suggest that the regenerative capacity and the 
plasticity of the endometrium may be suboptimal in obese women when 
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compared to that of normal weight women. This may potentially compromise the 
ability of the uterus to undergo intense tissue remodelling upon embryo 
implantation, thus increasing the risk of miscarriage and other pregnancy 
complications in obese women. However, it is important to acknowledge that 
other mechanisms, such as a chronic pro-inflammatory state associated with 
obesity, may also contribute to the increased risk of adverse reproductive 
outcomes (Denison et al., 2010). The clinical relevance of suboptimal CE of 
W5C5+ cells in an obesogenic environment is reinforced by the observation that 
the obese subjects had higher miscarriage rates when compared to either 
overweight or normal women. 
 
As discussed in previous chapters, maternal age is an important factor in 
determining successful pregnancy outcome. The risk of miscarriages and 
infertility significantly increase with advancing maternal age. However, this 
study did not find any significant differences in the abundance or CE of W5C5+ 
and W5C5− endometrial cells between the three age groups (less than 35 
years, 35-39.9 years and more than 40 years). Additionally, there were no 
significant correlations between the abundance and CE of W5C5+ and W5C5− 
cells and age. These are key findings which agree with the recognised concept 
that the age related decline in fertility and poor reproductive outcomes are likely 
to be associated with an ovarian disorder rather than endometrial dysfunction. 
 
My work could potentially translate into novel diagnostic (e.g. quantifying and 
characterizing W5C5+ and W5C5- endometrial cells) interventions for 
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reproductive failure. Further studies are required to understand the defined 
mechanisms that govern the activity of endogenous eMSCs and the recruitment 
of clonogenic cells into the dynamic endometrium. 
 
This is the first prospective study to present a significant association between 
W5C5 endometrial cells and their CE with BMI, age and reproductive outcome. 
The other strength of this study is that it was carried out specifically to address 
our hypothesis.  
 
A limitation of our study lies in the relatively small number of subjects studied. A 
further potential criticism is that we did not examine the cell density and CE of 
the cells from a control group i.e. women with no adverse pregnancy outcome. 
The study was performed on endometrial biopsies obtained from women in the 
mid-luteal phase as required for us to study other markers in the endometrium 
which has limited our understanding of the effect of BMI on these cells and their 
function in different phases of the menstrual cycle. Further studies looking at 
these two factors on eMSCs in adequately powered prospective studies would 
certainly be of interest. 
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6.5 Conclusions: 
 
The clonogenic eMSCs which are capable of producing endometrial stroma in 
vivo allow the human endometrium to display remarkable regenerative capacity 
and plasticity. Our observations suggest that these essential features of the 
endometrium may be suboptimal in obese women which may be responsible for 
the increased risk of reproductive complications associated with obesity. Our 
data provides a platform for future studies on endometrial stem cell research. 
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CHAPTER 7: 
THE EFFECT OF BMI ON DIFFERENTIATING 
ENDOMETRIAL STROMAL CELLS IN VITRO 
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7.1 Introduction: 
 
As described in detail in chapter 1, decidualisation is a process that involves 
endometrial stromal cell differentiation into specialized secretory decidual cells, 
altered local immune cell populations and remodelling of the spiral arteries 
(Brosens et al., 2002) and the endometrium acquires distinctive characteristics 
essential for pregnancy. Decidualisation is essential for the formation of the 
placenta by its ability to regulate trophoblast invasion, and to maintain 
homeostasis by resisting environmental and oxidative stress. Endometrial 
stromal cells (ESC) modulate local vascular and immune responses and act as 
biosensors of embryo quality upon decidualisation (Teklenberg et al., 2010). 
Impaired cyclic decidualisation disables natural embryo selection and 
predisposes to recurrent pregnancy failures (Salker et al., 2010). Differentiation 
of ESCs in primary cell cultures in-vitro reflects decidualisation in-vivo and can 
be achieved by stimulation of ESCs using cyclic AMP – a second messenger 
molecule, and a progestin – medroxyprogesterone acetate (MPA) (Brosens et 
al., 1999). Expression of decidualisation markers, prolactin (PRL) and Insulin 
like growth factor binding protein–1 (IGFBP1) can be measured using real time 
quantitative PCR analysis.  
 
Adipose tissue synthesizes and secretes several adipokines - proteins and bio 
active polypeptides, and hormones which are important not only for maintaining 
energy homeostasis, but can also influence reproduction by their action on 
various reproductive organs including the endometrium (Michalakis and Segars, 
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2010). Adipokines act as systemic inflammatory mediators making obesity a 
state of low-grade inflammation. The fat within the organs and in the peri-
vascular region also has significant metabolic effects (Lee et al., 2009). Obese 
pregnant women are found to have an increased systemic and placental 
inflammation and associated endocrine and immune functions (Stewart et al., 
2007; Challier et al., 2008). Should the chronic inflammation associated with 
obesity affect the peri-implantation endometrium of high BMI women, this may 
have implications for endometrial stromal decidualisation and subsequent 
placental development and thus on potential fertility and reproductive outcome. 
 
We recognise that decidualisation of ESCs is an important step for successful 
implantation and pregnancy, so we sought to investigate if obesity could have a 
deleterious effect on the endometrial support of early pregnancy. We studied 
the effect of obesity on the peri-implantation endometrium by utilizing an in-vitro 
model of endometrial stromal cell decidualization. There are no studies which 
looked at the effect of obesity on the ESC differentiation in vitro. 
 
I hypothesised that the decidual programming of the peri-implantation 
endometrium is perturbed in an obesogenic environment and set out to assess 
the decidualisation markers from differentiating ESCs obtained from normal 
weight and obese women. I also looked at differentiation of ESCs in artificially 
created obesogenic environment. 
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7.2 Materials and methods: 
 
As discussed in chapter 2 
 
7.3 Results: 
 
7.3.1 Demographic details: 
 
Endometrial tissue was obtained from a total of 12 women. The Shapiro-Wilk 
test for normality suggested that the data for BMI was normally distributed, 
whereas the data relative expression of IGFBP1 on day 4, relative expression of 
IGFBP1 on day 8, relative expression of PRL on day 4, relative expression of 
PRL on day 8 did not pass the normality test. When the data for above variables 
were transformed into log10 values, the Shapiro-Wilk test indicated that the data 
was normally distributed. The women were classified into two groups according 
to their BMI: BMI < 25 (n=6) and BMI > 25 (n=6) (Figure 7.1).  
 
 
 
 
169 
 
 
 
  
BMI < 25 
(n=6) 
  
BMI > 25  
(n=6)  
  
p 
 
BMI (Kg/m
2
)  
Mean (± SEM) 
  
22.87  
(.452) 
  
  
31.83 
(1.81) 
  
<.002**# 
 
Age in years 
Median (IQR) 
 
34 
(31.5 – 36.0) 
 
34.50 
(30.75 – 43.0) 
 
.699## 
 
Relative induction of 
IGFBP1 mRNA day 4 
Mean (± SEM) 
 
 
177.67 
(± 96.23) 
 
1538.05  
(± 1514.19) 
 
.937# 
 
Relative induction of 
IGFBP1 mRNA day 8 
Mean (± SEM) 
 
233.33  
(± 144.19) 
 
2092.08  
(±2031.70) 
 
.394# 
 
Relative induction of 
PRL mRNA day 4 
Mean (± SEM) 
 
912.20  
(± 416.60) 
 
510.67. 
 (± 287.45) 
 
.485# 
 
Relative induction of 
PRL mRNA day 8 
Mean (± SEM) 
 
2013.21  
(± 826.75) 
 
 1998.27 
(± 1161.02) 
 
.937# 
Table 7.1: Summary of BMI and relative expression of decidualisation markers. # - 
Independent samples T test; ## - Independent samples Mann-Whitney U test; ** - 
p=.001. There was no significant difference in the relative expression of both IGFBP1 
and PRL on day 4 and day 8 in both groups. 
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BMI < 25 
(n=6) 
  
BMI > 25  
(n=6)  
  
p 
 
Log10 relative induction of 
IGFBP1 mRNA day 4 
Mean (± SEM) 
 
 
1.06 
(± .69) 
 
1.05  
(± .70) 
 
.997# 
 
Log10 relative induction of 
IGFBP1 mRNA day 8 
Mean (± SEM) 
 
.96  
(± .69) 
 
1.80  
(± .56) 
 
.366# 
 
Log10 relative induction of 
PRL mRNA day 4 
Mean (± SEM) 
 
2.65  
(± .29) 
 
2.09 
 (± .37) 
 
.255# 
 
Log10 relative induction of 
PRL mRNA day 8 
Mean (± SEM) 
 
2.94  
(± .34) 
 
2.68 
(± .38) 
 
.610# 
 
Table 7.2: Summary of Log10 relative induction of decidualisation markers on day 4 and 
day 8. # - Independent samples T test with equal variances assumed. 
 
 
7.3.2 Effect of BMI on expression of decidualisation markers in 
differentiating ESCs: 
   
Independent samples Mann-Whitney U test indicated no significant difference in 
the relative expression of IGFBP1 on day 4, relative expression of IGFBP1 on 
day 8, relative expression of PRL on day 4, relative expression of PRL on day 8 
among the two groups (Table 7.1 and Figures 7.1 a & b). The relative induction 
of decidualisation markers were logarithmically transformed into Log10 variables 
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(Table 7.2) and an independent samples T test with equal variances assumed 
indicated no significant difference in the median relative expression of IGFBP1 
and PRL on days 4 and 8 amongst both BMI groups (Figures 7.1 c & d).   
 
a.    b.  
 
c. d.  
Figure 7.1: Box and Whisker plots showing the results of Independent samples Mann-
Whitney U test indicated no significant difference in the median relative expression of 
IGFBP1 and PRL on days 4 and 8 amongst different BMI groups (a) and (b). Data in 
median (± IQR). Note the logarithmic Y-axis. The Bar chart showing the above data 
logarithmically transformed into Log10 data and an independent samples T test results 
which indicated no significant difference in the relative expression of IGFBP1 and PRL 
on days 4 and 8 amongst both BMI groups (c) and (d). Data in mean ± SEM 
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7.3.3 Effect of supernatant from fat explants on expression of 
decidualisation markers in differentiating ESCs: 
 
The earlier experiments indicated that maternal characteristics, particularly the 
BMI, did not affect the differentiation of hESCs in-vitro. We hypothesized that 
absence of the obesogenic environment at the time of decidualisation to be the 
reason for this behaviour of hESCs. We aimed to create an artificial obesogenic 
environment in-vitro at the time of differentiation of hESCs to investigate the 
possible effects of metabolically active substances secreted by an excess 
adipose tissue on endometrial stromal compartment decidualisation. We 
obtained supernatant from adipose tissue explants from normal weight women 
and obese women and treated them to the differentiating ESCs for 24 hours.  
 
The results obtained indicated that the PRL expression was significantly 
inhibited in hESCs differentiating in supernatant from the adipose tissue 
explants of obese woman when compared to the other groups.  
 
Figure 7.2 (a) and table 7.3 demonstrate that there was a significant difference 
in the expression of PRL between the groups (F=50.15, df=2, p=.000). A 
Tukey’s HSD post-hoc test revealed that the PRL expression was significantly 
lower in the obese group when compared to CM group (p=.001) and also from 
the normal group (p=.001).  
 
Figures 7.2 (b) and table 7.3 indicate that the IGFBP1 expression was 
significantly lower between the groups (F=7.00, df=2, p=.035). A multiple 
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comparison post-hoc Tukey HSD test indicated no significant difference in the 
IGFBP1 expression between normal-CM and normal-obese groups, but a 
statistically significant difference between the obese group when compared to 
CM group (p=.032).  
 
 
   a.  b.  
Figure 7.2: Bar charts with error bars indicating the PRL and IGFBP1 transcript levels 
in timed endometrial biopsies treated with culture media (CM), supernatant from 
adipose tissue explants from normal weight women (Normal) and obese women 
(Obese). PRL (a) and IGFBP1 (b) mRNA levels normalised to L19 transcript levels. 
Data in mean ± SEM. *** - p=.001 and * - p=.032.  
 
 a.  
Table 7.3: Results of oneway ANOVA for PRL and IGFBP1 expression in decidualising 
hESCs treated with culture media (CM), supernatant from adipose tissue explants from 
normal weight (Normal) and obese (Obese) women 
 
 
 
*** * *** 
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7.4 Discussion: 
 
My study findings provide evidence for the first time that the differentiation of 
human endometrial stromal cells in-vitro is not affected by the BMI of the 
women. This is based on the observation that expression of PRL and IGFBP1, 
highly sensitive and specific decidual marker genes within the endometrium, is 
not impaired in primary cell cultures obtained from women of different 
categories, when they are exposed to a decidualising stimulus. The levels of 
these marker genes were significantly not different in the timed endometrial 
biopsies from women with a normal weight (BMI < 25) when compared to the 
endometrial samples obtained from overweight and obese women. Although our 
expression analysis was restricted only to PRL and IGFBP1 expression, the 
data has demonstrated that the maternal characteristics such as BMI does not 
have any significant effect on the differentiating stromal cells in-vitro.   
 
However, this study has also provided an interesting evidence that the decidual 
programming may be impaired in an obesogenic environment. The levels of 
PRL were significantly lower in the decidualising endometrial stromal cells 
treated with supernatant from adipose tissue explants obtained from obese 
women when compared to cells treated with either the plain culture media or the 
supernatant from adipose tissue explants obtained from normal weight women. 
The treatment of decidualising endometrial stromal cells to supernatant from 
adipose tissue explants obtained from normal weight women did not make any 
significant effect on the expression of IGFBP1 expression when compared to 
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cells treated with plain culture media, whereas, the addition of supernatant from 
adipose tissue explants obtained from obese women to decidualising 
endometrial stromal cells significantly inhibited IGFBP1 when compared to the 
cells treated with culture media only. These are important findings which 
indicate that the metabolically active substances in the adipose tissue from 
obese women exert an unfavourable effect on the endometrial preparation for 
embryo implantation and pregnancy.  
 
Previous studies have demonstrated that the perturbations in decidual 
transformation of the endometrial stromal compartment can have negative 
effects on the endometrial programming in preparation of pregnancy and can 
lead to poor reproductive outcome such as infertility, miscarriage and RMC 
(Salker et al., 2010; Salker et al., 2011). The PRL expression was demonstrated 
to be significantly impaired in decidualising hESCs from women with RMC when 
compared to decidualising cells from control women (Salker et al., 2010). Our 
study demonstrates that impaired decidualisation of resident stromal cells in an 
obesogenic environment may predispose to unfavourable reproductive 
outcomes by disabling embryo recognition and by disrupting maternal 
responses to embryonic signals. In our observational study, we have indeed 
demonstrated that obesity is associated with increased risk of miscarriage of 
early pregnancy (discussed in chapter 2). An associated shorter time to 
pregnancy intervals in obese women with RMC (as discussed in chapter 2) 
could also be explained by the impaired decidualisation leading to impaired 
endometrial receptivity and natural embryo selection that even allows delayed 
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implantation of developmentally compromised embryos and subsequent 
pregnancy loss. 
 
The strength of this study is that these findings are novel as hitherto there is no 
data outlining the effects of obesity on decidual programming of the 
endometrium which is an important mechanism that determines reproductive 
success. 
 
There are a few limitations to this study. Firstly, the adipose tissue samples to 
mimic the obesogenic environment were obtained from women undergoing 
caesarean section at term, and hence may not account for the gestational 
variations in the component and metabolic function of the adipose tissue. The 
adipocytokines, synthesized and secreted by adipose tissue, are a novel group 
of endogenous substances and the exact mechanism by which these 
substances cause their effect on the decidualising endometrium is not known. 
This is an area with potential for future research and therefore, future studies 
should be undertaken to address this point. The findings are all obtained from in 
vitro cultures of hESCs mainly concentrating on two decidualisation markers 
and hence may not strictly reflect the in vivo situation and hence, caution is 
needed in translating our findings to the clinical scenario. There are many other 
markers such as cytokines (Prokineticin-1; PROK1), regulators (SGK1, IL-33) 
and pro-inflammatory mediators (ST2) which are linked to decidualisation and 
further study to assess the expression of these markers would be required for a 
better understanding of the effects of obesity on decidualisation.  
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7.5 Conclusions: 
 
This study provides exciting novel data on the effects of the obesogenic 
environment on the decidual programming of the endometrium. Although, from 
our in-vitro study, we conclude that the effects of obesity may impair 
endometrial decidualization and could account for the unfavourable 
reproductive outcomes associated with obesity. Further work, however, is 
necessary to confirm these findings in larger studies and also to ascertain the 
exact underlying mechanisms which explain the metabolic effects of obesity on 
decidualisation. If confirmed, the findings present us with a novel therapeutic 
target to improve reproductive outcomes in obese women and suggest that 
improving decidualization may be of primary importance. 
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CHAPTER 8: 
SUMMARY OF FINDINGS AND CONCLUSIONS 
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In this thesis, firstly I have studied the clinical issue of the effects of obesity on 
fecundity and early pregnancy outcome from a large number of women 
attending a tertiary referral clinic with various reproductive failures and 
secondly, I have described the peri-implantation endometrium in normal and 
obese women by utilizing an in-vitro model which has provided a better 
understanding of uterine leucocytes, mesenchymal stem cells and stromal cell 
differentiation in the obese micro-milieu. From this study some interesting 
outcomes and significant differences amongst the study groups were identified 
which have generated further questions to future research. The findings of my 
research are summarised below: 
 
I have studied the current evidence on the effects of obesity on female 
reproductive health particularly looking at fertility, infertility treatment and 
miscarriage. The evidence from these studies, mainly observational and 
retrospective, suggests that obese women may be at an increased risk of 
adverse early pregnancy complications. I have also analysed and presented the 
clinical evidence on the possible effects of obesity on ovarian function, embryo 
development and the role of endometrium. There is a dearth of good quality 
evidence to conclude whether the metabolic effects of obesity are utero-centric 
or egg-centric, but it is likely that the endometrium may be most affected by 
obesity.  
 
In chapters 3 and 4, the clinical data identified supporting evidence superfertility 
existed in RM population and that superfertility was more prevalent amongst 
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obese than in normal weight women with a history of RM. I also identified that 
obesity increases the risk of first trimester miscarriages both in general 
population and in women susceptible to RM and that the obese women had an 
increased number empty gestational sac pregnancy losses (karyotypically 
normal - Morikawa et al., 2004)  compared to non-obese women in general 
population, but not in RM group. Both these findings and the available evidence 
suggest that in obese general population, the empty gestational sac losses are 
less likely to be karyotypically abnormal i.e. not due to oocyte abnormalities. 
Whereas the obese women with a history of RM when compared to normal 
weight counterparts, were more superfertile, and did not have a significant 
difference in the pregnancy loss pattern. This finding suggests of a possible 
impaired natural embryo ‘quality control’ process of the peri-implantation 
endometrium which allows both developmentally competent as well as 
compromised embryos to implant, but end up clinically as a miscarriage. 
 
Studies suggest that obesity is characterised by a local adipose tissue 
inflammation and reactive peripheral leucocytosis (Herishanu et al., 2006). An 
increased uNK cell density and decidual macrophages density has been 
reported in the endometrium of women with RMC (Lachapelle et al., 1996; 
Quenby et al., 1999, 2005, 2009; Tuckerman et al., 2007). However, my study 
as described in chapter 5, did not find any correlation between BMI and uterine 
leucocyte density in the immunohistochemical study of mid-luteal endometrial 
samples. I found no significant difference in the uNK cell density and 
macrophage density and any significant difference in the ratio of uNK cells to 
macrophage density in obese women when compared to normal weight women. 
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Further studies with larger numbers are warranted to investigate the correlation 
between macrophage density and first trimester miscarriages observed in our 
study and its significance. Hence, I conclude that the endometrial dysfunction in 
obese women with reproductive failure does not appear to be immune cell 
mediated. 
 
In chapter 6, I have demonstrated for the first time the negative impact of 
obesity on the regenerative capacity and plasticity of the endometrium. 
Clonogenic W5C5+ cells which are specialised eMSCs that characterise the 
human endometrium with an extraordinary regenerative capacity. There was no 
significant correlation between the relative abundance (%) of W5C5+ to W5C5- 
cells with BMI and no significant difference % of W5C5+ cells among BMI 
groups. The most interesting findings in this chapter were that of the negative 
correlation of CE of W5C5+ cells with BMI and the significantly reduced CE of 
W5C5+ cells in obese subjects when compared to normal weight subjects. Thus 
obesity appeared to have a deleterious effect on the clonogenecity of 
endometrial stem cells which is likely to be translated into endometrial 
dysfunction that the clinical data suggests. 
 
In chapter 7, I have demonstrated that obesogenic environment may possibly 
impair decidual programming of the endometrial stromal compartment, an 
essential mechanism that determines the reproductive success in the 
obesogenic environment. Initial data suggested that the in-vitro decidualisation 
of the human endometrial stromal cells based on the observation of expression 
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of decidualisation markers was not affected by the BMI. However, when 
decidualising endometrial stromal cells were treated with supernatant from 
adipose tissue explants obtained from obese women, the PRL expression was 
significantly inhibited when compared to the treatment with supernatant from 
adipose tissue explants obtained from normal weight women and also when 
treated only with culture media. The expression of the other marker, IGFBP1 
was significantly inhibited when decidualising endometrial stromal cells were 
treated with supernatant from adipose tissue explants obtained from obese 
women compared to the cells treated only with culture media. The exact 
mechanism for inhibition of decidualisation markers in the obese micro-milieu 
needs further investigation.   
 
In conclusion this work has provided initial evidence to the understanding of the 
peri-implantation endometrium in obese women. My data suggests that 
endometrial stromal function is possibly modulated by metabolic influences and 
that the increased risk of poor reproductive outcome in obese women has a 
molecular basis that lies in the endometrium. Future work with larger numbers 
and in-vivo studies in animal models are required to confirm these findings. If 
confirmed, clinical trials with therapeutic targets to improve decidualisation and 
thus reproductive outcome in obese women could hold significant clinical 
potential.  
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